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ABSTRACT

THE EFFECT OF MELATONIN UPON POST-ACUTE WITHDRAWAL AMONG
MALES IN A RESIDENTIAL TREATMENT PROGRAM (M-PAWS): A
RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

By
Corry D. Bondi, Ph.D.
December 2016

Thesis supervised by Vincent J. Giannetti, Ph.D.
The study goal was to assess melatonin as an adjuvant treatment along with
current pharmaco- and behavioral therapy for 28 days on weekly self-reported severity of
anxiety, depression, stress, and sleep complaints as well as how sleep is affecting daily
life in a sample of males in recovery from chemical dependency at a single, residential
treatment site, Salvation Army Harbor Light Center in Pittsburgh, PA. This study was a
single-center, randomized, double-blind, placebo-controlled, parallel group trial of 28
days. Participants were randomized to melatonin (5 mg) or placebo and instructed to
administer the intervention nightly at bedtime. Primary self-reported outcome measures
of severity of anxiety, depression, stress, as well as sleep complaints and how sleep is
affecting daily life were assessed on a weekly basis with the Generalized Anxiety
Disorder Scale (GAD-7), Personal Health Questionnaire Depression Scale (PHQ-8),
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Perceived Stress Scale (PSS-14), and Pittsburgh Sleep Symptom Questionnaire –
Insomnia (PSSQ-1). Secondary outcome measures were to acquire participant histories,
determine adherence as well as adverse events. Seventy participants (age 21 – 65, mean
40.4 ± 11 years) were enrolled with 24 completing the study in each group.
Demographically, the sample consisted of those who identified as white (70%), single
(74.3%), and with an education level of high school/G.E.D. or less (77.1%). Intention-totreat analysis for all outcome measures revealed statistically significant within-groups
differences over time for both groups. The study failed to demonstrate statistically
between-group differences for these measures. Also, complete case analysis for each
week revealed no between-group differences. Additionally, the change from Baseline
and Day 28 as determined by a response of an improvement of 50% or higher in scores
for each scale revealed no significant strength of association between the groups when
considering worst case for the loss to follow-up. Melatonin appeared to be well tolerated
with similar adverse events reported as placebo; however, there was a tendency to report
more vivid dreams/nightmares as well as next day tiredness/grogginess/sleepiness.
Clinical investigations into the use of melatonin as a treatment for depression, anxiety,
stress, and sleep difficulties in those recovering from illicit and non-illicit drug
dependency are limited and larger studies are warranted. Possible future directions
include a study design that is multicenter, the inclusion of a therapy only arm, assessing
various doses and timelines, assessing effects in adolescents or females, or limiting
inclusion based on prescribed medications, mental health status, medical conditions, prior
melatonin use, and/or a specific chemical dependency. Overall, this is the first and
largest randomized, double-blind, placebo-controlled, parallel group trial assessing the
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effects of melatonin upon post-acute withdrawal among males in a residential treatment
program. However, the various analyses indicated insufficient evidence to suggest that
melatonin and placebo were significantly different, and it may be concluded, based upon
the study sample, design, and its limitations, the effect of melatonin on the assessed
measures was no different than placebo. Due to the heterogeneity of the participants as
evidenced by the participant histories, there exists a possibility of a Type II error that
must be considered and not overlooked.
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BACKGROUND
In the United States (U.S.), chemical dependency (i.e., substance abuse or
substance use disorder) is a public health crisis that affects the behavioral and physical
health of the nation. It impacts communities, families, as well as contributes to crime,
homelessness, and other social problems and the etiology of chronic diseases such as
heart disease and diabetes (1, 2). The economic burden is high with cost estimates of
over $400 billion related to lost productivity, crime, and healthcare costs, of which, $36
billion is directly attributed to healthcare costs (3). Specifically, the costs associated with
alcohol dependency are $224 billion, of which, $25 billion is attributed to healthcare
costs while costs associated with illicit drug abuse is $193 billion and $11 billion,
respectively (3). Thus, finding ways to counteract this crisis is of national importance.
According to Koob and Simon (2009), “drug addiction is a chronically relapsing
disorder characterized by: (a) compulsion to seek and take the drug, (b) loss of control in
limiting intake, and (c) emergence of a negative emotional state (e.g., dysphoria, anxiety,
and irritability) when access to drug is prevented (4).” The Substance Abuse and Mental
Health Services Administration (SAMHSA) conducts the National Survey on Drug Use
and Health (NSDUH), the major source of information on the prevalence, patterns, and
consequences of illicit and non-illicit drug use and abuse in the general U.S. civilian,
noninstitutionalized population ages 12 and older (3, 5). According to the 2013 NSDUH,
there were approximately 22.4 million adults (9.4% of adults) reporting using illicit drugs
in 2013 in the past month and about 20.3 million adults (8.5% of adults) reported a past
year substance use disorder (5). Co-morbidity of a substance use disorder along with a
mental health condition is common. It is estimated that 7.7 million adults (3.2% of
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adults) have a substance use disorder co-occurring with a mental health condition as
defined by DSM-IV criteria (5). Importantly, individuals with mental health issues were
more likely to have a substance use disorder and vice versa; at least half of those who
develop an addiction have mental health conditions (6, 7).
Commonly abused drugs include opiates and narcotics (e.g., heroin & narcotic
pain medications), stimulants (e.g., amphetamine and cocaine), central nervous system
depressants (e.g., alcohol and benzodiazepines), hallucinogens (LSD and psilocybin), and
marijuana/hashish (6). Specifically, 18 million adults (7.6% of adults) reported using
marijuana or hashish followed by 4 million adults (2.5% of adults) who used prescription
drugs (i.e., pain medications) for nonmedical reasons (5). Marijuana use has increased
since 2007 and remains the most commonly reported first drug used (8). Use and abuse
of alcohol is common with 16.2 million adults, disproportionately males, reporting being
engaged in heavy drinking defined as “drinking five or more drinks on the same occasion
on five or more days in the past 30 days (5, 8).”
To alleviate the financial impact on the nation, prevention and early treatment
programs have been shown to be beneficial. For example, cost-benefit ratios, reported in
the Institute of Medicine and National Research Council’s Preventing Mental, Emotional,
and Behavioral Disorders among Young People Report – 2009, range from 1:2 to 1:10
meaning every $1 of investment yields $2-$10 in savings (2). As reported in the
Treatment Episode Data Set (TEDS) of admissions and discharges from substance abuse
treatment facilities, Whites (60%) accounted for the most admissions followed by
African-Americans (21%) and Hispanic or Latino (14%). The age range of 20-29 years
(29.2%) accounted for the highest proportion of admissions while the lowest being 65
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years or older (0.6%). The majority of those admitted sought treatment for alcohol abuse
(41.4%) with 18.3% of those abusing alcohol with another drug. Twenty percent of
admissions included heroin and other opiates, cocaine and other stimulants (17.8%), and
marijuana (17.0%) (9). Effective treatments are available but too many individuals fail to
get the treatment they need. The 2013 NSDUH reported that out of 22.7 million
individuals 12 years or older who needed treatment for alcohol or illicit drug use, only
2.5 million received treatment at a specialty facility (5). Individuals who needed but did
not receive treatment, felt a need for treatment, and made an effort face many barriers
including “no health coverage/could not afford cost (37.3%),” “not ready to stop using
(24.5%),” “did not know where to go for treatment (9.0%),” “had health coverage but it
did not cover treatment or did cover cost (8.2%),” and “no transportation or inconvenient
hours (8.0%) (5).” To address the coverage gap, the Affordable Care Act requires health
plans to cover essential benefits such as treatments for substance abuse (7).
Treatment begins by first identifying the problem with the overall goals to
empower the individuals to regain control of their lives as well as to improve the
behavioral health; both aimed at reducing the national burden of chemical dependency (5,
10). Because treatment is not a “one size fits all approach,” treatment programs aim to
understand addiction, prevent relapse, and utilize various combinations of counseling,
support networks, faith-based approaches, and medications (7, 11). A comprehensive
approach addresses a continuum of care including the components of health promotion,
prevention, treatment, and recovery. Tailoring a program to the needs and cultural
background of the individual is the optimal approach for successful recovery (2). The
program needs to understand the cultural context of the individual as well as implement
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community-based values, traditions, and customs. Integrated treatment approaches
focusing on treating mental health issues along with co-occurring substance use disorders
have increased value by displaying lower costs and improved outcomes as evidenced by
reduced substance use, decreased hospitalizations, improved mental health, increased
housing stability, reduced arrests, and enhanced quality of life (7). Residential treatment
programs apply techniques to allow individuals in recovery to recognize their behaviors
and to learn how to avoid relapse (6). Talk therapy sessions directed by a therapist or
counselor includes individual, group, or family in outpatient, residential, or inpatient
settings (7, 11). Medication-assisted treatment (MAT) seeks to control cravings and
other symptoms of withdrawal by blocking the reward pathways or induce negative
feelings when the addicting drug is used (7).
Once involved in a treatment program, the individual may enter withdrawal
therapy (detoxification) performed on an inpatient or outpatient basis in a supportive
environment with the goal of drug cessation in a rapid and safe manner (6, 11).
Depending on the drug, various approaches can be utilized such as titrating down the
dose of the drug, substitution with a prescribed drug such as methadone, or combining
treatment medications with behavioral therapy (11, 12). Recovery as defined by
SAMHSA is “a process of change through which individuals improve their health and
wellness, live self-directed lives, and strive to reach their full potential (10).” Hope is the
foundation of recovery, and recovery is built upon the individual’s talents, strengths,
coping abilities, resources, and inherent values. During recovery, one may experience
many setbacks, but the focus rests on improvements to health and wellness (10). Overall,
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it is important for the individual to maintain their abstinence and to cope with life
challenges without relapse (2).
Relapse after detoxification is extremely high if relapse prevention counseling is
not initiated. A number of techniques to prevent relapse include seeking help
immediately upon drug use, avoiding high-risk environments, maintaining one’s
treatment plan such as meeting with counselor, and going to support sessions (11). If
relapse occurs, a new treatment program may need to be developed or the prior treatment
program may need to be reinstated or adjusted (12).
Generally, individuals in recovery will transition from acute withdrawal to postacute withdrawal. During post-acute withdrawal, recovered individuals will experience a
variety of emotional and psychological symptoms (i.e., post-acute withdrawal syndrome:
PAWS) including, but are not limited to, anxiety, sleep difficulties (e.g., sleep latency
and duration), depression, and stress with symptoms tending to be episodic and lasting
for up to two years. To alleviate PAWS, individuals are usually prescribed
pharmacotherapies and/or instructed to effectively use coping techniques of practicing
self-care, relaxation, and cognitive therapies (13).
Because of the symptomatology of post-acute withdrawal, melatonin therapy may
be beneficial. Melatonin is widely used in a non-regulated manner to alleviate insomnia
and evidence shows that melatonin contributes to the sleep/wake cycle by initiating and
maintaining sleep, decreasing sleep latency, improving sleep quality, next day alertness,
and quality of life (14). In addition to insomnia, evidence reported in the literature
suggests that melatonin may also decrease anxiety and depressive symptoms as well as in
individuals with co-morbid insomnia (15-19). Melatonin (0.75 mg, nightly, 10 days)
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improved the emotional state in anxious young individuals (15). An intermediate-release
formulation of melatonin, melaxen (1.5 mg, nightly, 2 weeks), decreased levels of
depression and anxiety in a group of healthy volunteers (16). In alcohol dependent
patients who were not consuming alcohol for at least 14 days prior, melaxen (3 to 6 mg,
nightly, 3 weeks) decreased anxiety (17). Melatonin administration may be beneficial for
improving sleep in individuals with co-morbid depression and sleep disturbances.
Individuals with delayed sleep phase syndrome with depressive symptoms given
melatonin (5 mg, 4 weeks) reported decreases in depression scores (18). In an open pilot
study, patients with depression and sleep disturbances given melatonin (3 mg orally,
nightly, 21 days) exhibited improved sleep quality and reduced awakening within 2 to 3
days (19)
Alcohol dependent individuals experience difficulties with sleep latency and
maintenance possibly due to alterations in nocturnal melatonin levels. In a study of
alcoholic individuals, circulating nocturnal melatonin levels were found to be lower
during the early part of the night and had a delay in the nocturnal rise (20). In a trial of
alcohol dependent patients who were not consuming alcohol for at least 14 days prior,
melaxen (3 to 6 mg, nightly, 3 weeks) improved quality, latency, duration of sleep,
breathing during sleep, as well as decreased daily sleepiness (17).
Research regarding nightly, orally administered melatonin has demonstrated the
following: is well tolerated, has no abuse potential, does not induce rebound insomnia or
withdrawal symptoms, does not affect endogenous melatonin production, does not impact
psychomotor, performance, mood, or cognitive functions, does not negatively affect
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hepatic and renal function (14, 21-24). These findings are important considering that it
will be administered to individuals in recovery.
There is a paucity of literature demonstrating the effects of melatonin in
individuals experiencing PAWS. As aforementioned, previous studies have shown that
melatonin therapy is beneficial in alleviating anxiety, depressive symptoms, and
insomnia. However, no randomized, double-blind, placebo-controlled trials have been
conducted in males who are experiencing PAWS. The goal of this study is to test a
therapeutic approach that incorporates the addition of melatonin to the current treatment
program of males who are in a residential treatment program for chemical dependency.
The purpose of the study was to assess the effect of 5 mg melatonin compared to placebo
as an adjuvant treatment along with their current pharmaco- and behavioral therapy for
28 days on weekly self-reported severity of anxiety, depression, stress, and sleep
complaints as well as how sleep is affecting daily life in a sample of males in recovery
from chemical dependency at a single, residential treatment site.
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PURPOSE, HYPOTHESIS, and OUTCOME MEASURES
Purpose
The purpose of the study was to assess the effect of 5 mg melatonin compared to
placebo as an adjuvant treatment along with their current pharmaco- and behavioral
therapies for 28 days on weekly self-reported severity of anxiety, depression, stress, and
sleep complaints as well as how sleep is affecting daily life in a sample of males in
recovery from chemical dependency at a single, residential treatment site.
Hypotheses
1) Melatonin along with current pharmacotherapy and behavioral treatment
regimen will affect sleep complaints and how sleep is affecting daily life compared to
placebo along with current pharmacotherapy and behavioral treatment regimen treatment
regimen in males participating in a residential treatment program.
2) Melatonin along with current pharmacotherapy and behavioral treatment
regimen will affect severity of anxiety, depression, and stress compared to placebo along
with current pharmacotherapy and behavioral treatment regimen in males participating in
a residential treatment program.
Primary outcome measures
1.) To determine the effect of melatonin or placebo along with current treatment
regimen on the change in severity of anxiety as measured by the Generalized Anxiety
Disorder Scale (GAD-7).
2.) To determine the effect of melatonin or placebo along with current treatment
regimen on the change in depressive symptoms as measured by the Personal Health
Questionnaire Depression Scale (PHQ-8).
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3.) To determine the effect of melatonin or placebo along with current treatment
regimen on the change in stress as measured by the Perceived Stress Scale (PSS-14).
4.) To determine the effect of melatonin or placebo along with current treatment
regimen on the change in sleep complaints and how sleep is affecting daily life as
measured by the Pittsburgh Sleep Symptom Questionnaire – Insomnia (PSSQ-1).
5.) To determine response of each individual as an improvement of 50% or higher
in score for each scale (i.e., change from Baseline to Day 28).
Secondary outcome measures
1.) To acquire participant histories (social, medical, medication, preventive,
mental health, chemical dependency, and melatonin use, if any)
2.) To determine adverse events experienced while taking the intervention.
3.) To determine adherence to study interventions of melatonin or placebo
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INTRODUCTION
Substance use disorder (SUD)
Substance use disorder is defined as “a dependence on legal or illegal drugs or
medication” and is diagnosed by a licensed mental health professional using criteria in
the Statistical Manual of Mental Disorders (DSM-V), published by the American
Psychiatric Association (11). According to Koob and Simon (2009), “drug addiction is a
chronically relapsing disorder characterized by: (a) compulsion to seek and take the drug,
(b) loss of control in limiting intake, and (c) emergence of a negative emotional state
(e.g., dysphoria, anxiety, and irritability) when access to drug is prevented (4).” The
following is a selected list of addiction symptoms and behaviors provided by the Mayo
Clinic (for a more complete list consult reference): “feeling that you have to use the drug
regularly,” “having intense urges for the drug,” “needing more of the drug to get same
effect,” “maintain a supply of the drug,” “spending more money on the drug,” and
“focusing more and more time and energy on getting and using the drug (11).”
Exposure to risk factors greatly increases the probability of becoming dependent
on drugs and these risk factors vary with the type of drug, environment, genetics, and
development (11, 12). Specific factors include family history of addiction, lack of family
involvement, male gender, initiating drug use at an early age, mental illness, peer
pressure, and as a coping mechanism to deal with mental health issues including, but not
limited to, depression and anxiety (11, 12). At least half of those who become dependent
struggle with mental health issues (6). Moreover, the 2013 NSDUH estimated that 7.7
million adults (3.2% of adults) had a substance use disorder along with a mental health
issue as defined by DSM-IV criteria (5).
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Before becoming dependent, an individual progresses through several stages of
drug use: experimental use, regular use, problem/risky use, and then
addiction/dependence (6). While chemically dependent, the individual physically needs
the drug and larger doses of the drug in order to function normally in their daily life and
continues to use despite the deleterious effects to their physical and mental health as well
as to a host of societal problems including work, family, financial, and legal. The
individual also finds it difficult to cease drug use because discontinuance leads to
cravings (psychological dependence) and abrupt stoppage leads to withdrawal symptoms
(11).
Neurobiology
Addiction
To date, the reinforcing effects of addicting drugs have been linked to site of
action - receptors and transporters, and the neurocircuitry involved - dopamine and opioid
systems (4). In general, the brain is a collection of neurons that communicate through the
use of chemicals called neurotransmitters (e.g., serotonin, gamma-aminobutyric acid
(GABA), and dopamine). The process of addiction results in modifications in the brain
thus resulting in changes in the behavior of the individual. Withdrawal from the addicting
drug produces dysphoria suggesting alterations of the same neural systems involved with
its reinforcing effects (4). Addicting drugs act via mimicking endogenous
neurochemicals, or by overstimulating the reward system of the brain. For example,
heroin and marijuana mimic endogenous neurochemicals to exert actions through
receptors. Dopaminergic reward systems (movement control, emotion, motivation, and
pleasure) of the brain are modified during development of addiction and stimulants, such
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as amphetamine and cocaine, produce effects via increasing release of dopamine or
preventing its reuptake by the neurons from the synapse resulting in an overstimulation
and the subsequent euphoric effects. Over time, the neuroadaptation is to produce less
dopamine or reduce the number of dopamine receptors thereby attenuating the effect of
dopamine on the reward system leading to the use of more drug to prevent dysphoria –
drug tolerance (12). Human imaging studies revealed decreases in dopaminergic function
(25) and the mesocorticolimbic dopamine system has been an area of focus of the
positive reinforcing effects of addicting drugs (26). Evidence suggests that dopamineindependent neurocircuitry located in the nucleus accumbens and amygdala have a role in
reward. Research is demonstrating a role of nondopaminergic systems being involved
with drug dependence. Other neurochemicals are affected during addiction; for example,
changes in glutamate levels may have a role in affecting cognition. In summary, longterm use of drugs leads to neuroadaptations in neurochemical levels and brain regions
controlling a multitude of functions such as executive, cognition, and behavior (12).
Modifications of the reward system leads to increased intake of addicting drugs, and it is
these adaptive changes that lead to addiction. Dopamine-dependent and -independent
actions by dopamine, opioid peptides, serotonin, and GABA are involved with positive
reinforcement while modifications in the reward system during dependence include the
decreases in the aforementioned as well as recruitment of stress systems that contribute
the negative motivational state during cessation (27).
Cessation
Because of the neuroadaptations that occurred in the brain during addiction,
cessation of drug use is difficult (12). As drug use progresses, tolerance is achieved
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where the amount of drug needed to produce the same euphoric effect increases due to
changes in neurocircuitry and molecular targets (e.g., receptors). To avoid the negative
effects of drug cessation, the individual needs the drug to prevent the physical illness,
cravings, and dysphoria (11). Addicting drugs produce dysphoria upon cessation
suggesting that the neuroadaptations that occurred during addiction may involve the same
systems involved with the positive reinforcing effects. As such, the dysphoria and
anxiety associated with cessation probably involve decreases in the reward system and
recruitment of stress neurocircuitry (4). Collectively, during drug cessation, decreases in
levels of neurochemicals and resulting transmission occur with dopamine, serotonin,
GABA, and dynorphin but increase levels and transmission of glutamate and
norepinephrine suggesting that neuroadaptations occur in systems that are involved with
positive reinforcing effects during dependence as well as systems involved with stress
and arousal (4, 27).
After drug detoxification, the individual will experience less physical symptoms
but more psychological and emotional symptoms due to the remodification of the
neuroadaptations where the brain chemistry is attempting to return to pre-drug state. This
second stage of withdrawal is commonly known as PAWS. The symptoms include, but
are not limited to, anxiety, sleep disturbances (e.g., sleep latency and duration), and
depression; these symptoms may occur for up to two years post drug cessation. The
symptoms of PAWS tend to be episodic; for example, symptoms may last for days and
then disappear before re-expressing at a later date. Treatment modalities usually involve
instruction on the use coping techniques such as practicing self-care, relaxation, and
patience (13).
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Melatonin (N-acetyl-5-methoxytryptamine)
Melatonin therapy may be beneficial to those experiencing PAWS. In the U.S.,
melatonin is readily available as a non-regulated, nutraceutical and used for treating sleep
disorders. It is commonly found in doses of 0.5 mg, 1 mg, 3 mg, and 5 mg. Melatonin
contributes to regulating the sleep/wake cycle, and its synthesis and release follows a
diurnal rhythm. In response to darkness, melatonin is synthesized in and then secreted
from the pineal gland with peak plasma levels occurring at 02:00 (2 am) (28, 29);
however, exposure to light attenuates norepinephrine release from sympathetic nerve
terminals resulting in reduced synthesis of melatonin (30, 31). Because of variation in
daily light exposure, seasonal fluctuations exist; for example, during the summer months
when the day is longer, the duration of action of melatonin will be shorter compared to
winter months (32).
The actions of melatonin are through receptor independent (e.g., free radical
scavenging) and dependent mechanisms (e.g., MT1 or MT2 melatonin receptors). Upon
receptor binding, the melatonin/melatonin receptor complex elicits effects on intracellular
proteins that may ultimately impact gene transcription (32-38). Melatonin receptors are
ubiquitously expressed throughout the body including expression in the brain (39, 40).
Melatonin has very low toxicity with a high margin of safety. However, adverse
events have been reported; for example, orally administered melatonin may cause vivid
dreaming or daytime grogginess, but these events usually dissipate with continued use.
Other adverse events an individual may experience include drowsiness, headache,
dizziness, small changes in blood pressure, or nausea. Research regarding nightly, orally
administered melatonin has demonstrated the following: is well tolerated, has no abuse
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potential, does not induce rebound insomnia or withdrawal symptoms, does not affect
endogenous melatonin production, does not impact psychomotor, performance, mood, or
cognitive functions, does not negatively affect hepatic and renal function (14, 21-24).
Due to its lipophilicity, melatonin readily distributes to most tissues and crosses
the blood-brain barrier. In humans, oral bioavailability is about 33% with serum levels
peaking within one hour. Melatonin undergoes phase I metabolism in the liver by the
cytochrome P450 enzyme, CYP1A2, to 6-hydroxymelatonin before phase II metabolism
by sulfotransferases to 6-sulfatoxymelatonin (αMT6). Up to 85% of a given dose is
excreted in the urine (41). Importantly, melatonin levels are affected by various classes
of drugs (e.g., psychotropic medications) that induce, inhibit, or act as a substrate of
CYP1A2 (42).
Melatonin and mood disorders
Levels of melatonin and/or αMT6
The noradrenergic system is involved in the production of melatonin as well as in
the pathophysiology of depression. Individuals with depression have disruption of the
nightly rhythm of melatonin whereby the onset of melatonin secretion occurs later in the
night. Results of a study of 14 inpatients (7 males and 7 females) with major depression
at the end of a psychotropic medication-free period (14 matched controls for age, gender,
season, and hormonal treatment), published by scientists at the Universite de Liege in
Belgium, revealed a significant delay in the nightly melatonin peak in depressive patients
suggesting a phase-shifting of melatonin production; however, there were no differences
in mean level or peak of melatonin. In the depressive group, urinary levels of αMT6
were higher in the morning compared to night time levels while the urinary levels of the
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control group displayed the characteristic lowering from night to morning (43). The
degree of depression as well as living in a different hemisphere may impact the secretion
of melatonin. In a study of 32 psychotropic medication-free patients (9 males and 23
females) with major depression (32 matched controls for age and gender) and another 15
drug-free outpatients (5 males and 10 females) with major depression (matched controls
for age, gender, body mass index, and season) from São Paulo, Brazil, the following was
documented, urinary levels of αMT6 during the 24 hour and 6 hour periods were similar
between depressed and control groups suggesting that alterations in nightly melatonin
production may occur only in more severe depression and in the northern hemisphere
(44).
Melatonin as a treatment
In anxious young individuals, melatonin (0.75 mg, nightly, 10 days) improved
their emotional state (15). Studies investigating the effects of melatonin using an
intermediate-release dosage form on anxiety and depression demonstrated an
improvement in levels of depression and anxiety. For example, in a group of healthy
volunteers, melaxen (melatonin IR, 1.5 mg, 2 weeks) decreased levels of depression and
anxiety (16).
Melatonin and sleep disorders – insomnia
Levels of melatonin and/or αMT6
Individuals suffering from insomnia experience late onset of sleep or early
morning awakening which may be a result of a shift in the circadian rhythm by either
delaying or advancing it, respectively. Individuals with insomnia have alterations in the
nightly secretion pattern of melatonin. One of the first studies to investigate the possible
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alteration in secretion pattern in individuals experiencing difficulties maintaining sleep
(i.e., experiencing frequent awakenings) was performed by a group at University of
Gottingen in Germany. Results of the study revealed that plasma levels of melatonin
increased earlier in the evening and were lower in the middle of the night compared to
controls (peak value of 82.5 ± 26.5 pg/ml versus 116.8 ± 13.5 pg/ml, respectively).
Moreover, the levels of melatonin were the most severely reduced in individuals who
experienced difficulties for more than five years (peak value 72.1 ± 25.0 pg/ml) (45).
Melatonin as a treatment
Because of its role in circadian systems, melatonin supplementation has been
shown to be beneficial for the treatment of sleep dysfunctions. A meta-analysis
investigating the effects of exogenously administered melatonin on sleep conducted by
Brzezinski et al. (2005) determined, that even though the pooled data were
heterogeneous, melatonin reduced sleep onset latency by 4 to 7.5 minutes, increased
sleep efficiency (the ratio of total sleep time to time in bed) by 2.2%, and increased total
sleep duration by 12.8 minutes (46). Results from a prospective 6 to 12 month openlabel study of 244 community dwelling adults (aged 20 to 80 years) with insomnia (112
completed study 6 months and the other 96 completed 12 months) demonstrated that
prolonged-release melatonin (2 mg, nightly, 6 to 12 month followed by a 2 week
withdrawal) significantly increased the number of nights with sleep quality reported as
“good” or “very good” compared to before treatment (22). In the European Union (E.U.),
Circadin (prolonged-release 2 mg melatonin) was approved in 2007 for short-term
treatment of primary insomnia in individuals aged 55 and older. Clinical trials have
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demonstrated improvements in onset of sleep latency, sleep quality, next day alertness,
and quality of life (21).
However, melatonin has also been shown to improve sleep latency in individuals
without sleep dysfunctions. In a group of young healthy volunteers without sleep
disorders, melatonin (0.3 or 1 mg, nightly) reduced onset of sleep latency as well as
latency to stage 2 sleep. Additionally, neither dose altered sleep architecture, the pattern
of sleep as it changes between sleep stages (14).
Melatonin and comorbidities
Melatonin as a treatment
Individuals experiencing major depressive disorder frequently experience sleep
difficulties. Antidepressant medications are generally ineffective in combating sleep
issues, and the addition of benzodiazepines to the medication regimen is not without
concerns. Because of its role in circadian systems and its low abuse potential, melatonin
supplementation may be beneficial for improving sleep in individuals with comorbidities
such as depression. Results of those completing a double-blind, placebo-controlled trial
beginning with 24 outpatients 22 - 65 years of age (19 completed study) demonstrated
that the 10 individuals with major depressive disorder given slow release melatonin (5
mg up to 10 mg) along with fluoxetine for four weeks reported significant improvement
of scores on the Pittsburgh Sleep Quality Index (PSQI) compared to the nine taking
placebo and fluoxetine. However, no differences were detected in the rate of
improvement in depressive symptoms compared to those given fluoxetine plus placebo.
Of importance, the slow-release melatonin did not increase the onset of fluoxetine (47).
In an open pilot study, elderly individuals with signs of depression and sleep disturbances
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as well as those only experiencing sleep disturbances were given melatonin (3 mg,
nightly, 21 days) and within 2 to 3 days improvements in sleep quality and reduced
awakenings were demonstrated in those with or without depression (19). The largest
RCT at time of publication involved 33 individuals with major depressive disorder where
15 were given slow release melatonin (6 mg, nightly, 4 weeks). Findings demonstrated
significant improvement of subjective but not objective measures of sleep as well as for
mood; however, results were not specific to melatonin (i.e., placebo effect) (24). In a
randomized, double-blind, crossover, placebo-controlled study testing if exogenous
melatonin can reduce depressive symptoms in individuals with delayed sleep phase
syndrome (DSPS), individuals with DSPS and depressive symptoms (n = 8) and DSPS
without depressive symptoms (n = 12) were enrolled. Interventions were given for four
weeks with one week washout in between. Melatonin decreased depression scores as
assessed by the Epidemiologic Studies Depression Scale (CES-D) and Hamilton
Depression Scale-17 in both study groups compared to placebo. Assessment of αMT6
revealed those with DSPS and depressive symptoms had alterations in melatonin rhythms
compared to those without depressive symptoms (18).

19

SYSTEMATIC LITERATURE REVIEW
Even though melatonin and its analogues have been used in studies of anxiety,
depression, and insomnia, the purpose of this study was to investigate the effect of
melatonin upon PAWS among individuals in recovery from chemical dependency.
Therefore, the specific objectives of this systematic review were: 1.) to identify studies
that assessed melatonin levels in the blood and/or αMT6 levels in the urine of chemically
dependent individuals or those who have undergone withdrawal, 2.) to identify studies
that used melatonin or its analogs as a treatment in chemically dependent individuals or
those who have undergone withdrawal, and 3.) the use of melatonin to facilitate the
withdrawal of benzodiazepine administration and/or its effect on health conditions during
benzodiazepine withdrawal.
The literature search was conducted in Pubmed on June 7, 2016 with no time
restriction (Figure 1). The search was set to return only studies conducted in humans.
After the search was performed, the results were further filtered manually by the author
to exclude meta-analyses, reviews, systematic reviews, studies without an abstract
available, and published study protocols. Abstracts written in English language were
included regardless of original language of respective article. Articles were included if
they met criteria as stated in the aforementioned objectives. The search strategy included
the following terms: (“Melatonin”[tiab] OR “Melatonin”[OT] OR “Melatonin”[mesh]
OR “Ramelteon”[tiab] OR “Ramelteon”[OT] OR “6-sulfatoxymelatonin”[tiab] OR “6sulfatoxymelatonin”[OT]) AND (“Chemical Dependency”[tiab] OR “Substance
abuse”[tiab] OR “Substance use disorder”[tiab] OR “Addiction”[tiab] OR
“Alcoholism”[tiab] OR “Illicit drug use”[tiab] OR “Drug dependence”[tiab] OR
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“Substance dependence”[tiab] OR “Alcohol dependent”[tiab] OR “substance
withdrawal”[tiab] OR “post acute withdrawal”[tiab] OR “Chemical Dependency”[OT]
OR “Substance abuse”[OT] OR “Substance use disorder”[OT] OR “Addiction”[OT] OR
“Alcoholism”[OT] OR “Illicit drug use”[OT] OR “Drug dependence”[OT] OR
“Substance dependence”[OT] OR “Alcohol dependent”[OT] OR “substance
withdrawal”[OT] OR “post acute withdrawal”[OT] OR “Substance-Related
Disorders”[Mesh] OR “Behavior, Addictive”[Mesh] OR “Street Drugs”[Mesh]).
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106 articles identified through
database search (Pubmed)

Articles Excluded:
30 articles were reviews
12 studies were without abstract available
1 studies were published study protocol

63 studies were reviewed

Meeting the criteria of the
objectives, 20 studies were
included.
13 studies met Objective #1
3 studies met Objective #2
4 studies met Objective #3
Figure 1. Schematic representation of methodology used and selection criteria.
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Melatonin and chemical dependency
Objective #1: Levels of melatonin and/or αMT6
Substance use disorder
Compared to alcohol use disorder (9 articles), the literature review revealed fewer
articles (4 articles) investigating plasma levels of melatonin and/or its metabolite in
individuals with substance use disorder demonstrating a necessity for more research.
Veit and colleagues investigated circadian hormone profiles in 13 cases of
politoxicomania compared to 10 persons in a good state of health. Cases were divided up
into three groups: Group 1: complete abstinence, Group 2: no hard drug intake, and
Group 3 acute relapse after a prolonged period of abstinence. Melatonin levels were
higher in the group of “abstinents” compared to acute relapsive cases (48).
As part of a larger study, an exploratory study of 21 adolescents, 14 males and
seven females, (mean age of 16.3 ± 1.35 yr, range 14 – 19 yr) who experience sleep
complaints or daytime sleepiness and have completed substance abuse treatment eight
weeks prior were enrolled. Participants kept sleep diaries, wore an actiwatch for seven
days, completed behavioral and psychological measures, and spent one night for dim
light melatonin onset assessment where salivary samples were collected every 30 minutes
beginning at 19:30 to 03:30. Participants demonstrated disordered sleep and older
adolescents showed later dim light onset. Considering that adolescents commonly have a
delayed phase, a substantial number of participants had early dim light onsets. Overall,
the authors highlight the following: the participants have a wide range of dim light onset
with delays associated with the older adolescents, the onsets were associated with longer
sleep onset latency, and finally, onsets and shorter phase angles between sleep offset and
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dim light onset were significantly related to higher severity of substance abuse issues
(49).
A study sought to investigate 24 hour levels of urine αMT6 in 11 opiatedependent individuals during opiate withdrawal while undergoing in-patient methadone
detoxification. Levels were assessed during methadone stabilization and on Days 6 and
12 of withdrawal treatment. Compared to stabilization (i.e., baseline), urine levels were
significantly higher on Day 6 but not on Day 12. There existed a correlation between
withdrawal symptom score severity and urine levels during stabilization and Day 6 (50).
In 13 females with heroin addiction (mean age of 31.7 ± 2.4 yr) compared to 17
healthy females (mean age of 30.0 ± 1.7 yr), levels of plasma melatonin were
significantly lower at baseline and six months after heroin withdrawal suggesting
melatonin levels did not fully recover. In those with heroin addiction, three and six
months after drug withdrawal, melatonin levels significantly increased compared to
baseline, but there existed no significant difference between three and six months (51).
Alcohol use disorder
In healthy men, acute alcohol exposure may not influence nocturnal melatonin
secretion in contrast to chronic exposure in those with dependency (52). Alcohol
dependent individuals experience difficulties with latency and maintenance of sleep that
may be attributed to phase-shifting and decreased levels of nocturnal melatonin secretion.
In a study of 10 male chronic alcoholic individuals before and after two weeks of
abstinence, urine melatonin levels as collected in two fractions (08:00 – 20:00) and
(20:00 – 08:00) revealed that 24 hour levels were higher in individuals during alcohol
intake compared to sex and age-matched controls. Moreover, higher day fraction levels
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were detected in these individuals as well as after alcohol withdrawal. Overall, the ratio
of night fraction over day fraction approximated “1” during intake and became greater
than “1” after withdrawal like the controls (53).
As an addition to a larger, worldwide, multinational control study sampling
depressed and abstinent alcohol dependent men and women from Sweden and California,
urinary melatonin levels were found to be similar between the two control groups as well
as between the depressed and alcoholic groups. However, the levels of the depressed and
alcoholic groups were significantly lower than the control groups (54).
The 24 hour, day- and nighttime melatonin levels were assessed in 10 alcohol
dependent men during active drinking and two weeks after withdrawal. Results revealed
increased daytime levels of urine melatonin and the inversion of the ratio between nightand daytime levels during active drinking that normalized upon withdrawal (55).
A study of 24 hour plasma levels of melatonin in eight chronic alcohol dependent
males in a detoxification program and eight healthy controls, levels were assessed on the
first day of alcohol withdrawal and after 14 days. The mean 24 hour levels were higher
during acute withdrawal compared to after 14 days of abstinence and those of the healthy
controls. Significance could not be determined due to larger inter-individual differences.
Based on cosinor analysis, there existed a loss of circadian periodicity in the acute phase
but periodicity was significantly restored after 14 days (56).
Research regarding ten chronically alcohol dependent individuals (mean 11.7 year
alcohol use with range 2 to 30 year, mean 219 g alcohol daily with range from 60 g to
360 g, and mean age 47.3 years with range 33 to 64 years), nighttime levels of blood
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melatonin were disrupted where more than 50% had low secretion (<30 pg/mL) during
the four days of alcohol withdrawal (57).
Another study investigated melatonin levels in alcohol dependent individuals with
or without delirium tremens during and 1 month after withdrawal. Individuals with
delirium tremens had disrupted serum levels during withdrawal that normalized after
withdrawal; however, those without delirium tremens had normal rhythm during and after
withdrawal (58).
In the absence of major pre-existing or concomitant psychiatric disorders, 11
alcohol dependent individuals, who underwent withdrawal 14 days prior, had sampling of
blood melatonin performed every 30 minutes beginning at 22:00 to 06:30. Results
revealed that levels were lower during the early part of the night as well as a delay in the
onset of the plateau or peak value compared to controls with the delay correlating with
the prolonged sleep latency as determined by polysomnography (20).
A study investigated the inversion of melatonin circadian rhythm in seven alcohol
dependent individuals during acute withdrawal (along with benzodiazepines) and 15 days
later (without psychotropic medications). Results demonstrated that in over half the
individuals the levels of urine αMT6 showed that the inversion of melatonin rhythm
persisted during acute withdrawal and continued to persist at 15 days in three individuals
(59).
Research investigating dim light melatonin onset in 52 abstinent alcohol
dependent individuals compared to 19 age- and sex matched healthy controls showed a
slower rate of rise of levels of salivary melatonin and decreased maximal peak in
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abstinent individuals. Specifically focusing on when melatonin levels were increasing,
there existed a significant delay of 18 minutes in abstinent individuals (60).
Objective #2: Melatonin as a treatment
In the U.S., melatonin is readily available as a non-regulated, nutraceutical
commonly used by individuals experiencing sleep disorders such as insomnia. Because
of the high abuse potential of hypnotic medications (e.g., benzodiazepines) or issues with
tolerability and daytime sedation associated with use of sedating psychotropic
medications, melatonin may be a safer and more appealing treatment option. Moreover,
literature shows melatonin may have anxiolytic and antidepressive actions (15, 16, 18,
24). However, research is limited as to the effects of melatonin on anxiety, depression,
and insomnia in individuals in recovery from chemical dependency.
Eryshev and collaborators investigated the effects of melaxen in 45 alcohol
dependent individuals with sleep and mild mood disorders. Initiated 14 days after
alcohol withdrawal, melaxen (melatonin IR, 3 to 6 mg, nightly, 3 weeks) decreased the
mood disorders especially anxiety as assessed with the Hamilton Anxiety Rating Scale
(HAM-A). In addition to studying the effects of melaxen on anxiety and depression, selfreported sleep quality and sleepiness were also assessed with a sleep quality
questionnaire and the Epworth sleepiness scale, respectively. Melaxen improved sleep
onset and duration and quality of sleep as well as decreased daily sleepiness (17).
Case series studies have been performed to assess the effects of ramelteon or
agomelatine, structural analogs of melatonin that act as MT1 and MT2 melatonin receptor
agonists with agomelatine also acting as a 5-hydroxytryptamine2c antagonist, in alcohol
dependent individuals with insomnia in the absence of other psychiatric disorders except
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nicotine dependence. Both studies were limited by a small sample size and an absence of
a placebo group. Ramelteon (8 mg, nightly, 4 weeks) was taken by four females and one
male, ages 32 - 53 years with alcohol dependency. Abstinence was initiated in the past 2
- 13 weeks. Remelteon improved insomnia scores on the Insomnia Severity Index (ISI),
reduced onset of sleep latency by about 0.5 hour, and increased total sleep time by more
than 1 hour (61).
Agomelatine (25 mg to 50 mg, nightly, 6 weeks) was investigated in abstinent
eight males and one female, mean age of 47.2 ± 11.2 years, with mean alcohol
dependency of 20 ± 8.3 years. Several individuals were weaned off their sleeppromoting substances; however disulfram treatment was maintained. After six weeks of
treatment, global sleep quality scores obtained from the PSQI significantly decreased
(62).
Objective #3: Melatonin use in benzodiazepine withdrawal
Following an extensive literature review, four articles revealed mixed results for
use of melatonin to facilitate benzodiazepine withdrawal. In an RCT of 34 older
individuals (9 men, 25 women, mean 68 ± 13 yr) who were undergoing benzodiazepine
treatment for six months, melatonin (2 mg controlled release: Circadin) or placebo was
administered nightly for six weeks. Individuals were directed to reduce their dosage of
medications by 50% during week 2, 75% during weeks 3 and 4, and then to discontinue
completely. By the end of the study, 14 of 18 (77%) individuals in the melatonin group
discontinued medications compared to 4 of 16 (25%) in the placebo group. Sleep quality
scores were significantly increased in the melatonin group compared to placebo group
indicating an improvement in sleep quality. When melatonin was administered to
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individuals in the placebo group, six more discontinued their benzodiazepine usage. At 6
month follow-up, 19 (79%) of those who discontinued usage of benzodiazepines and
who continued using melatonin remained abstinent and had a significantly improved
sleep quality compared to baseline scores (63).
A randomized, double-blind, placebo-controlled, cross-over control study of 80
individuals enrolled at a community methadone maintenance clinic was performed to
investigate the effect of melatonin in reducing sleep difficulties during benzodiazepine
withdrawal. Melatonin (5 mg/day) or placebo was administered for 6 weeks with a 1
week washout before cross-over for another 6 weeks. Results revealed that the
discontinuation rate of those 61 individuals who completed the six weeks of treatment
was similar. In those that continued using benzodiazepines, sleep quality as measured by
the PSQI improved in those who took melatonin first compared to those who took
placebo first; however, no difference was found between groups in those who ceased
usage (64).
A randomized, double-blind, placebo-controlled, cross-over study was conducted
investigating the effect of melatonin on behavioral disorders and sleep in 22 individuals
(7 men, 15 women over 65 years of age) and the facilitation of hypnotic medication
cessation in 14 of those individuals with melatonin (5 mg/day) or placebo being
administered for two months. Sleep disorders were measured with the Northside
Hospital Sleep Medicine Institute (NHSMI) and behavioral disorders with Yesavage
Geriatric Depression Scale (GDS) and Goldberg Anxiety Scale (GAS). Melatonin
improved sleep quality scores compared to baseline and placebo and improved the scores
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of behavioral disorders assessed. During melatonin treatment, hypnotic medication
cessation occurred in nine out of 14 individuals (65).
An RCT investigated the efficacy of melatonin as an adjuvant in sedative
withdrawal in 92 men and women, over 55 years of age presenting with primary
insomnia and long-term sedative usage. Melatonin (controlled release, 2 mg) or placebo
were administered during the 1 month withdrawal along with psychosocial support.
After 1 month, the reduction of sedative use was similar between groups. At the 6 month
follow-up, similar numbers of individuals remained abstinent (n = 14 melatonin and n =
20 placebo), but the doses of those still using were significantly higher in the melatonin
group compared to placebo. These findings suggest that melatonin provided no benefit
compared to placebo when attempting to withdraw from sedative use (66).
Summary of literature review
As stated previously, melatonin levels begin to rise during the hours of darkness.
In individual with depression, the onset of nightly melatonin secretion occurs later which
may be related to severity of depression. The evidence suggests, however limited, that
nightly administration of melatonin provides a benefit in individuals experiencing mood
disorders such as depression and anxiety. Investigations into melatonin secretion in those
suffering from insomnia reveal alterations in the nightly secretion of melatonin. Of
interest, one of the first studies to investigate the possible alteration in secretion pattern in
individuals experiencing difficulties maintaining sleep (i.e., experiencing frequent
awakenings) found plasma levels of melatonin increased earlier in the evening and were
lower in the middle of the night compared to controls. Moreover, levels of melatonin
were the most severely reduced in individuals who experienced sleep difficulties for more

30

than five years. A meta-analysis investigating the effects of exogenously administered
melatonin on sleep determined that melatonin reduced sleep onset latency by 4 to 7.5
minutes, increased sleep efficiency (the ratio of total sleep time to time in bed) by 2.2%,
and increased total sleep duration by 12.8 minutes. When focusing on those individuals
experiencing major depressive disorder with sleep difficulties, research also suggests that
melatonin may be beneficial for improving sleep in individuals with comorbidities such
as depression. Collectively, these findings provide evidence of the effectiveness of
melatonin administration in those dealing with depression, anxiety, insomnia, or with
comorbidities of insomnia and depression. Even though the research was conducted in
those individuals not in recovery from illicit or non-illicit drug use, these findings provide
a rationale for investigating its effects in individuals in recovery from illicit drug and
alcohol use.
Individuals in recovery have a high prevalence of mental health symptoms along
with substance abuse history. Also, sleep complaints and how their difficulties with sleep
impact their daily life are common and a cause of concern. After drug detoxification, the
individual will experience psychological and emotional symptoms (i.e., PAWS). The
symptoms include, but are not limited to, anxiety, sleep disturbances, and depression;
these symptoms may occur for up to two years post drug cessation and tend to be
episodic. These individuals also have multiple prescription medication use including
psychotropic medications such as antidepressants that are generally ineffective in treating
sleep issues. Because of the high abuse potential of hypnotic medications (e.g.,
benzodiazepines) or issues with tolerability and daytime sedation associated with use of
sedating psychotropic medications (e.g., trazadone and quetiapine), melatonin may be a
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safer and more appealing treatment option. Thus, melatonin administration may be
beneficial to those experiencing PAWS. In the U.S., melatonin is readily available as a
non-regulated, nutraceutical and commonly used for treating sleep disorders because
melatonin contributes to regulating the sleep/wake cycle. Melatonin has very low
toxicity with a high margin of safety and research regarding its use has demonstrated the
following: it is well tolerated; has no abuse potential; does not induce rebound insomnia
or withdrawal symptoms; does not affect endogenous melatonin production; does not
impact psychomotor, performance, mood, or cognitive functions; and does not negatively
affect hepatic and renal function. These are important concerns when considering
administering melatonin to individuals in recovery.
The purpose of this study was to investigate the effect of melatonin upon postacute withdrawal among males in recovery from chemical dependency. Therefore, three
specific objectives were formulated before conducting the systematic review: 1.) to
identify studies that assessed melatonin levels in the blood and/or αMT6 levels in the
urine of chemically dependent individuals or those who have undergone withdrawal, 2.)
to identify studies that used melatonin or its analogs as a treatment in chemically
dependent individuals or those who have undergone withdrawal, and 3.) the use of
melatonin to facilitate the withdrawal of benzodiazepine administration and/or its effect
on health conditions during benzodiazepine withdrawal. The systematic literature review
uncovered 20 articles relating to the three objectives. The majority of articles explored
melatonin levels in the blood and/or αMT6 levels in the urine of individuals during or
after withdrawal from alcohol (9 articles) or other substance use (4 articles). The
consensus of literature provides evidence that in abstinent alcohol dependent individuals,
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nightly melatonin secretion tends to be phase-shifted (i.e., delayed) with decreased
nocturnal levels suggesting that temporal disruption and magnitude of melatonin
secretion may explain why alcohol dependent individuals experience difficulties with
latency and maintenance of sleep.
Only three and four articles met the criteria for Objective #2 and #3, respectively.
Based on the review, there seems to be a paucity of studies investigating the use of
melatonin as a treatment in this population. Even though the case series studies involving
melatonin analogues revealed improvements in sleep in abstinent alcohol dependent
individuals with insomnia in the absence of other psychiatric disorders, these studies
were limited by a small sample size and an absence of a placebo group. Regarding
Objective #3, the literature revealed mixed results for use of melatonin to facilitate
benzodiazepine withdrawal. Overall, research is limited as to the effects of melatonin on
anxiety, depression, and insomnia in individuals in recovery from chemical dependency.
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METHODS
Drugs
Melatonin [73-31-4] (#5250)
Trial design
Full board approval was obtained from the Institutional Review Board at
Duquesne University and then registered as a clinical trial on Clinicaltrial.gov (Identifier:
NCT02431728, Received: April 28, 2015) prior to the study implementation. The trial
was a single-center, randomized, double-blind, placebo-controlled, parallel-group trial
conducted in males 18 years of age and older who are in a residential treatment program
for chemical dependency at the Salvation Army Harbor Light Center (865 West North
Avenue, Pittsburgh, Pennsylvania, 15233) in the U.S. Convenience sampling was used to
recruit individuals from July 2015 to December 2015. A total sample of 70 participants
were enrolled and block randomized with an allocation ratio of 1:1 for the interventions,
5 mg melatonin and placebo. Financial compensation of $5.00 U.S. was initiated at Day
7 and continued at each follow-up (Day 14, Day 21 & Day 28). Intention-to-treat and
complete case analyses were performed; however, no interim analysis was performed to
assess efficacy. Participants completed study materials in a designated room at the
center.
Briefly, this study involved the completion of four validated surveys assessing
self-reported severity of anxiety (Generalized Anxiety Disorder Scale; GAD-7),
depression (Personal Health Questionnaire Depression Scale; PHQ-8), stress (Perceived
Stress Scale; PSS-14), and sleep complaints and how is sleep affecting daily life
(Pittsburgh Sleep Symptom Questionnaire – Insomnia; PSSQ-1) at five time points
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(Baseline, Day 7, Day 14, Day 21, and Day 28). At enrollment, an individual expressing
interest was provided with an informed consent form by the investigator (CDB) and was
instructed to read the consent form prior to the investigator (CDB) verbally reviewing the
contents of the form. At this time, questions were addressed, if any. It was paramount
that informed consent was obtained through the willingness of the individual and not
through a perception of coercion. The investigator stressed that participation was
voluntary, would not involve any foreseeable financial costs, and lack of participation
would not affect their treatment or status at the center. Furthermore, it was stressed that
the participant can withdraw at any time; however, the data collected will be used.
Upon providing informed consent, a business-sized card labeled with the study
identification number was provided. If needed, this card will be presented at the weekly
follow-ups in order to obtain his opaque manilla envelope, labeled with his unique study
identification number, containing the four self-report surveys and financial compensation.
After informed consent, the participant completed the health history form containing
questions addressing social, medical, medication, preventive, mental health, chemical
dependency, and melatonin histories. The participant proceeded to complete the four
self-report surveys, GAD-7, PHQ-8, PSS-14, and PSSQ-1. If the participant had
requested help, the investigator (CDB) read the survey question/s, and then provided an
interpretation of what the question/s was/were asking, if needed. Upon completion, all
forms were enclosed in the manilla envelope by the participant, and then placed into a
secured container by the investigator (CDB). The study intervention (a capsule card
containing either 5 mg melatonin and Avicel® or the placebo containing only Avicel®)
was provided along with specific instructions to administer one capsule by mouth at
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bedtime (center “lights out” at 24:00) for 28 days. If a dose was missed, the capsule was
to remain sealed in the card. The investigator (CDB) stressed that it was imperative to
maintain adherence to current pharmacotherapies as prescribed. To address any adverse
events relating to the interventions, the participant was encouraged to report any adverse
events to the investigator (CDB). The participant was also encouraged at the weekly
follow-ups to report if any new symptoms were experienced during the past week other
than those experienced at time of study entrance. All adverse events were documented.
At the conclusion of each weekly follow-up, willingness to remain in the study was
verbally assessed. Those participants who completed the 28-day study were prompted to
answer the question, “Do you believe you were taking melatonin – Yes or No?” To
protect the anonymity and confidentiality of the participants, all paperwork were deidentified but contained the unique identification number. All data containing materials
were secured in the office of the investigator (CDB) at Duquesne University. Only the
principle investigator (VJG) and the co-investigators (CDB & PWE) had access to the
data. Dr. Adam Gordon, the physician on record at the center, was aware of the study.
Participants
Eligible participants were males 18 years of age and older who had a recent
history of chemical dependency and also have co-occurring mental health diagnosis,
medical conditions, legal system involvement, and/or a history of homelessness. Study
inclusion criteria were residence at the Harbor Light Center, willingness to participate in
the 28-day study, willingness to provide social, medical, medication, preventive, mental
health, chemical dependency, and melatonin histories, willingness to complete selfassessments of severity of anxiety, depression, stress, and sleep complaints and how sleep
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is affecting daily life, willingness to administer daily at bedtime the intervention, and the
ability to read and speak English. Participants were excluded if currently selfadministering melatonin or had an adverse history with melatonin supplementation.
Recruitment
Recruitment was conducted via study flyers displayed at the center, counselors
notifying residents, residents notifying residents, investigator (CDB) notifying residents
twice a week before one of their therapy sessions, and investigator (CDB) having
discussions with interested resident/s.
Settings and locations
The study was conducted at the Salvation Army Harbor Light Center (865 West
North Avenue, Pittsburgh, Pennsylvania, 15233). Pittsburgh is a major city located in
Allegheny County with a population of 300,000 and 1,230,000, respectively (67). From
2005 to 2010, the metropolitan statistical area (MSA), counties of Allegheny, Armstrong,
Beaver, Butler, Fayette, and Washington, consists of 2.1 million persons aged 12 or older
with 1.9 million being adults aged 18 or older. According to the NSDUH Report:
Substance Use and Mental Disorders in the Pittsburgh MSA, an estimated annual mean of
281,000 persons aged 12 or older (13.4%) used an illicit drug and about 182,000 persons
aged 12 or older (8.7%) had a substance use disorder in the past year. Also, an estimated
116,000 adults aged 18 or older (6.1%) experienced a major depressive episode in the
past year. These rates were similar to rates of the State and nation (68).
The Harbor Light Center is a Pennsylvania Department of Drug & Alcohol
Program (DDAP) licensed, medically-monitored long-term (3-month), and residential
substance abuse rehabilitation program for men. It is a 40-bed, residential treatment
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program for men 18 years of age and older who have a recent history of chemical
dependency along with co-occurring mental health diagnosis, medical conditions, legal
system involvement, and/or a history of homelessness. Requirements for program entry
are residency in Allegheny County and possessing a valid Pennsylvania state
identification. Residents follow a daily schedule that includes therapy sessions and three
meals. The program is aimed to individuals with varying degrees of dependency, and the
facility is a place where men are cared for physically, mentally, and spiritually in order to
allow each man to realize his worth, value, and personhood. Services provided include
group therapy that incorporates relapse prevention, gratitude, life skills, psychiatric
medication evaluation, and rational emotive and mental health therapies. Additionally,
individual therapy, assignment to an Allegheny County D&A case manager to assist with
housing and other community-based resources, and meetings with Office of Vocational
Rehabilitation counselor to aid with educational resources and work are offered. MAT is
not provided.
Interventions
Participants were randomly assigned to receive capsules containing either 5 mg
melatonin plus Avicel® filler or the placebo containing only Avicel®. Avicel® is a
microcrystalline cellulose powder commonly used by the pharmaceutical industry. All
study capsules were compounded by Jeffreys Drug Store (1 North Central Avenue, Ste.
#1, Canonsburg, PA, 15317). The capsules were packaged in non-child resistant, foilbacked cards delivering a 30-day supply (Washington Medical Equipment). A number
from 1 to 30 appeared next to each foil-backed capsule corresponding to the day in the
study. Even though the study was for 28 days, two extra capsules were provided in case
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of quality, loss, or sanitary issues were encountered. Capsules were clear, matched for
size, and the formulation within appeared as a white, microcrystalline powder. Melatonin
and Avicel® are tasteless. Capsule content was independently confirmed by the
laboratory of Kevin J. Tidgewell, Ph.D. (Assistant Professor of Medicinal Chemistry,
Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA)
using high performance liquid chromatography (See Appendix).
Outcomes
The primary outcome measures were to determine the effect of melatonin or
placebo along with current treatment regimen on the change in severity of: 1.) anxiety as
measured by the GAD-7, 2.) depression as measured by the PHQ-8, 3.) stress as
measured by the PSS-14, and 4.) sleep complaints and how sleep is affecting daily life as
measured by the PSSQ-1. Surveys were completed at five different time points
(Baseline, Day 7, Day 14, Day 21, and Day 28). Also, the change from Baseline and Day
28 was determined by a response of an improvement of 50% or higher in the survey
scores for each scale. Secondary outcome measures were to acquire participant histories
(social, medical, medication, preventive, mental health, chemical dependency, and
melatonin use), determine any adverse events through self-report, and determine
adherence to study interventions.
Instruments
Evaluation methods utilized structured, self-reported surveys: GAD-7, PHQ-8,
PSS-14, and PSSQ-1. An investigator generated form was used to collect social,
medical, medication, preventive, mental health, chemical dependency, and melatonin
histories. Importantly, each designated time frame as indicated on the surveys was used
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to assess baseline measures; then, each time frame was changed to “over the last seven
days” for the other follow-up times. For the PSSQ-1, mean scores of each subscale were
determined, and the scale was not used to assign a diagnosis of insomnia disorder.
The GAD-7 measures self-reported severity of anxiety. It is a 7-item scale
assessing severity as measured by a symptom checklist over the last two weeks. It
employs a 4-point scale with the response options of “Not at all” (0 pts), “Several days”
(1 pt), “More than half the days” (2 pts), and “Nearly every day” (3 pts). Severity is
based on the sum total where 15 - 21 is considered “severe anxiety (69).”
The PHQ-8 measures self-reported degree of depression. It is an 8-item scale
assessing degree as measured by a symptom checklist over the last two weeks. It
employs a 4-point scale with the response options of “Not at all” (0 pts), “Several days”
(1 pt), “More than half the days” (2 pts), and “Nearly every day” (3 pts). The higher the
sum total the greater the degree of depression; for example, a score of 20 or more is
considered severe major depression (70).
The PSS-14 measures self-reported degree of stress. It is a 14-item scale
assessing degree as measured by a checklist of the individual’s thoughts and feelings
during the past month. It employs a 5-point scale with the response options of “Never”
(0 pts), “Almost Never” (1 pt), “Sometimes” (2 pts), “Fairly Often” (3 pts), and “Very
Often” (4 pts). Because some questions are positively stated, scores are obtained by
reversing the scoring on items 4, 5, 6, 7, 9, 10, and 13, for example a score of “4”
becomes a score of “0”. The scores are summed with higher score indicating more
perceived stress (71).
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The PSSQ-1 measures self-reported severity of sleep complaints and how sleep
affects daily life. It is a 13-item scale that assesses severity during the past month with
two subscales: Sleep complaints (Questions 1-5) and how sleep is affecting daily life
(Questions 6-13). Sleep complaints are assessed by a 6-point scale with the response
options of “Never” (0 pts), “Do not know” (1 pt), “Rarely” (2 pts), “Sometimes” (3 pts),
“Frequently” (4 pts), and “Always” (5 pts) and asks “How long has the symptom lasted.”
To assess for how sleep is affecting daily life, it employs a five point scale with the
response options “Not at all” (0 pts), “A little bit” (1 pt), “Moderately” (2 pts), “Quite a
bit” (3 pts), and “Extremely” (4 pts) (72). Mean scores for each subscale were
determined.
Sample size
The study involved repeated measures (Baseline, Day 7, Day 14, Day 21, Day
28), within-between (Intervention by Time) research design. The independent variables
were intervention (melatonin and placebo) and time (Baseline, Day 7, Day 14, Day 21,
and Day 28). The dependent variable was mean self-reported score. G*power 3.1.9 was
used to perform a power analysis for ANOVA: Repeated measures, within-between
interaction. Statistical power (1 - βerror probability) of 0.80 with a small effect size of
0.15 was selected. The Type 1 error (α) probability was 0.05. Based on the analysis
(total sample size = 56) and adjusted to account for predicted loss to follow-up of <20%,
a total of 70 individuals were enrolled.

41

Randomization
To ensure equal treatment allocation of 1:1, block randomization with a block size
of four and a scheme of AABB, BBAA, ABAB, BABA, ABBA, and BAAB (sequence
repeated) was used to randomize all 70 participants (73).
Allocation concealment mechanism and implementation
The consent form, health history form, surveys, financial compensation envelope,
capsule card labeled with a study ID number, and study identification card (business
sized card with ID number) were contained in, according to allocation sequence,
sequentially numbered (1-70), opaque manilla envelopes individually secured by a metal
clasp. Allocation concealment (e.g., preparing envelopes) was performed by a student
volunteer from the Mylan School of Pharmacy at Duquesne University. Implementation
procedures were performed by investigator (CDB). After receiving informed consent, the
manilla envelope was opened revealing the study identification card, and then the study
identification number was placed on the front of the envelope.
Blinding/Masking
Study interventions (i.e., capsule cards) were provided by the manufacturer to the
principal investigator (VJG) in two boxes labeled “A” and “B.” Sealed envelopes
containing the key were provided by the pharmacy. One sealed envelope was maintained
in a secured location in the office of the principle investigator (VJG) and another sealed
envelope was provided to the center director (SL). A sealed envelope was provided to
the center director for safety purposes (e.g., hospitalization of participant). According to
allocation sequence, capsule cards were then labeled on the back in the lower right-hand
corner with the study identification number. Another set of sealed envelopes were
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generated enclosing the key for this scheme. These envelopes were also provided to and
maintained by the principle investigator (VJG) and the center director (SL). The overall
randomization key, linking box letter to study identification number, was maintained as
an electronic file on the computer of the investigator (CDB). The investigators and
participants were blind to intervention allocation. Participants were also unaware of the
exact intervention received. Upon completion of the last participant completing the last
survey day, the study was unmasked to the investigators (VJG, CDB, & PWE) by
comparing the randomization key to the contents of both unsealed envelopes.
Statistical methods
No interim analysis was performed to assess efficacy. Data obtained from the
health histories were tallied and reported as percentages, as warranted. To determine if
significant differences exist in the data obtained from the health histories between the two
groups, Fisher’s exact, Chi-square, or unpaired t-tests (two-tailed) were performed. The
study involved a repeated measures (Baseline, Day 7, Day 14, Day 21, Day 28), withinbetween (Intervention by Time) research design. Intention-to-treat analysis, in which all
participants were analyzed in the group to which they were assigned, and complete case
analysis, in which all participants who completed the 28 day study, were performed. To
analyze the data obtained from those fulfilling the intention-to-treat and complete case
criteria, a two-way ANOVA (Intervention by Time, two-tailed) followed by a Tukey’s
multiple comparison test was performed.
The change from Baseline to Day 28 of each participant was dichotomized as
either a response or no response. Response was defined as improvement of 50% or
greater in the survey scores (GAD-7, PHQ-8, PSS-14, and PSSQ-1) from Baseline to Day
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28. For those lost to follow-up, the participants were assumed to have no response (i.e.,
assumed worst case). The proportion of response/no response were compared across
groups with contingency table analysis by performing a Fisher’s exact test (two-tailed, CI
95%). Strength of association were reported as relative risk (95% CI). GraphPad Prism
6 software (GraphPad Software Inc., La Jolla, CA) was used to perform the statistical
analyses. Significance level was α = 0.05 (CI 95%) for all tests. Significance, if any,
was defined as p ≤ 0.05, p ≤ 0.01, p ≤ 0.001, and p ≤ 0.0001 as indicated by (*), (**),
(***), and (****), respectively.
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RESULTS
Participant recruitment, allocation, follow-up, and analysis
From July 2015 to December 2015, 70 potential participants were randomized to
either the experimental group (Melatonin, n = 35) or the comparison group (Placebo, n =
35). It was revealed at Day 21 that one participant was not taking the intervention (i.e.,
placebo), and the data was excluded except for baseline. Intention-to-treat and complete
case analyses were performed.
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Assessed eligibility, n = 70
Randomized, n = 70

Allocated to melatonin
(experimental group),
n = 35
Received allocated intervention,
n = 35

Allocated to placebo
(comparison group)
n = 35
Received allocated intervention
n = 35

Attended follow-up
Day 7, n = 32
Day 14, n = 30
Day 21, n = 26
Day 28, n = 24

Attended follow-up
Day 7, n = 32
Day 14, n = 31
Day 21, n = 26
Day 28, n = 24

Analyzed
Intention-to-treat, n = 35
Complete case, n = 24

Analyzed
Intention-to-treat, n = 35
*One participant not taking intervention
Complete case, n = 24

Figure 2. Flow diagram for participant recruitment, allocation, follow-up, and analysis.
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Reasons for loss to follow-up
Table 1 presents the reasons and percent of loss to follow-up. The study retained
68.6% of the participants (a loss to follow-up of 31.4%), and was similar between the two
groups. The most prevalent reason was non-illicit or illicit drug relapse. These
participants were detected at the center to be under the influence of alcohol (n = 2),
benzodiazepines (n = 2), heroin (n = 3), or opiates (n = 3). Because of administrative rule
violations, four participants had to leave the center. Two participants withdrew due to
adverse events of tiredness (melatonin) and diarrhea (placebo). One individual withdrew
immediately after completing surveys at baseline (placebo). One death by possible drug
overdose was recorded. This participant was allowed to leave the center for the weekend
and was found deceased on a city street. Statistical analysis revealed no significant
differences between the two groups for loss to follow-up.
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Table 1
Loss to Follow-up
Variable

Total

Melatonin

Placebo

70

35

35

Loss to Follow-up, n (%)
Baseline

0 (0.0)

0 (0.0)

0 (0.0)

D7

6 (8.6)

3 (8.6)

3 (8.6)

D14

9 (12.9)

5 (14.2)

4 (11.4)

D21

18 (25.7)

9 (25.7)

9 (25.7)

D28

22 (31.4)

11 (31.4)

11 (31.4)

Reasons, n (%, % yes)
Adverse Event

22 (31.4)

11 (15.7)

11 (15.7)

2 (2.9, 9.1)

1 (2.9, 9.1)

1 (2.9, 9.1)

Adherence w/ Intervention

1 (1.4, 4.5)

0 (0.0, 0.0)

1 (2.9, 9.1)

Administrative

4 (5.7, 18.2)

1 (2.9, 9.1)

3 (8.6, 27.3)

Death (drug overdose)

1 (1.4, 4.5)

1 (2.9, 9.1)

0 (0.0, 0.0)

10 (14.3, 45.5)

5 (14.3, 45.5)

5 (14.3, 45.5)

Withdrew

2 (2.9, 9.1)

1 (2.9, 9.1)

1 (2.9, 9.1)

Work

1 (1.4, 4.5)

1 (2.9, 9.1)

0 (0.0, 0.0)

Unknown

1 (1.4, 4.5)

1 (2.9, 9.1)

0 (0.0, 0.0)

n

Relapse

% yes is defined as the number of those lost to follow-up for a specific reason
divided by the total number lost to follow-up multiplied by 100.
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Baseline self-reported social and current medication histories
Table 2 presents the self-reported social and current medication histories at
baseline. The sample had a mean age of 40.4 ± 11 years (range of 21 – 65 and median
39), and consisted mostly of participants who identified as white (70%), single (74.3%),
and with an education level of high school/G.E.D. or less (77.1%). Age was not reported
by two participants in the Melatonin group and one participant in the Placebo group.
Sixty-five participant (92.9%) reported currently taking prescribed medications (i.e.,
those medications expected to be taken during the 28-day study). The mean number of
medications prescribed was 3.5 ± 2.2 (range of 0 - 11, median 3, and mode 3). There
were 75 different prescribed pharmacotherapies including nutraceuticals for a total of 242
with most medications being used for treating conditions of the central nervous and
cardiovascular systems. If all nutraceuticals (e.g., vitamins, minerals, and supplements),
except for folic acid (vitamin B9) because of its use in treating anemia as well as folate
deficiency associated with alcoholism and liver disease, were excluded, there remained
70 different pharmacotherapies accounting for 231 total medications (Data not shown).
One participant reported antivirals for HIV/AIDS. Statistical analyses revealed no
significant differences between the two groups for age, race, marital status, education,
medication history, or mean number of medications prescribed.
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Table 2
Self-reported Social and Current Medication Histories at Baseline
Variable
n
Age, years
Mean, SD*

Total

Melatonin

Placebo

70

35

35

40.4 ± 11.0

39.5 ± 11.9

41. 3 ± 10.3

Range

21 - 65

21 - 65

25 - 63

Median

39

37

41

Race, n (%)
White

49 (70.0)

25 (71.4)

24 (68.6)

Black/African American

17 (24.3)

8 (22.9)

9 (25.7)

4 (5.7)

2 (3.2)

2 (3.2)

Other
Marital Status, n (%)
Single

52 (74.3)

26 (74.3)

29 (74.3)

Divorced

14 (20)

5 (14.3)

9 (25.7)

Other

4 (5.7)

4 (11.4)

0 (0.0)

54 (77.1)

30 (85.7)

24 (68.6)

3 (4.3)

1 (2.9)

2 (5.7)

College (attended or completed)

13 (18.6)

4 (11.4)

9 (25.7)

Medication History, n (%)
Yes

65 (92.9)

32 (91.4)

33 (94.3)

Medications
Mean, SD

3.5 ± 2.2

3.7 ± 2.3

3.2 ± 2.2

0 - 11

0-9

0 - 11

Education, n (%)
High School/G.E.D. or less
Technical School

Range
Median

3

4

3

Mode, n

3 (15)

5 (7)

3 (10)

Different Medications, #

75

53

58

Medications, #
Antiviral (HIV/AIDS), # (%)

242

129

113

2 (0.8)

0 (0.0)

2 (1.8)

Cardiovascular, # (%)*

43 (17.8)

29 (22.5)

14 (12.4)

Central Nervous, # (%)

157 (64.8)

82 (63.6)

75 (66.4)

9 (3.7)

2 (1.5)

7 (6.2)

Gastrointestinal, # (%)

9 (3.7)

3 (2.3)

6 (5.3)

Nutraceuticals, # (%)*

11 (4.5)

8 (6.2)

3 (2.7)

Respiratory, # (%)

1 (0.4)

0 (0.0)

1 (0.9)

Other, # (%)*

10 (4.1)

5 (3.9)

5 (4.4)

Endocrine, # (%)

*Age was not reported by two participants in the Melatonin group and by one
participant in the Placebo group.
*Nutraceuticals included vitamins, minerals, and supplements; however,
folic acid (vitamin B9) was included in "Cardiovascular." NSAIDS were included
in "Other;" however, aspirin was included in "Cardiovascular."
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Baseline self-reported medical history
Table 3 presents the self-reported medical histories identifying the total number
of conditions reported for each system as well as the most reported condition for each
system at baseline. Sixty–two participants (88.6%) reported a medical condition
diagnosed by a doctor with a mean of 3.0 ± 3.1 (range 0 – 18, median 2, and mode 1). In
aggregate, the participants tended to present with histories of high blood pressure,
heartburn/acid reflux, hepatitis, arthritis, and/or neuromuscular symptoms related to disc
herniation. One participant reported a history of HIV/AIDS. However, the category of
“Neurological/Psychiatric Events” did not address mental health conditions such as
anxiety, bipolar, depression, and schizophrenia; these were reserved for the mental health
history questionnaire (See Table 5). Statistical analyses revealed no significant
differences between the two groups for the mean number of diagnosed medical
conditions as well as the number of participants reporting conditions for each system.
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Table 3
Self-reported Medical History at Baseline
Variable
n
Medical History, n (%)
Yes
Medical Conditions
Mean, SD
Range
Median
Mode, n
Cardiovascular, #
Yes, n (%)
High Blood Pressure, n (%, % yes)
High Cholesterol, n (%, % yes)
Endocrine, #
Yes, n (%)
Diabetes, n (%, % yes)
Gastrointestinal, #
Yes, n (%)
Heartburn/Acid Reflux, n (%, % yes)
Genitourinary/Renal, #
Yes, n (%)
Kidney Stones, n (%, % yes)
Hepatic/Gall Bladder, #
Yes, n (%)
Hepatitis, n (%, % yes)
Musculoskeletal/Spinal, #
Yes, n (%)
Arthritis, n (%, % yes)
Cervical or Lumbar Disc, n (%, % yes)
Neck/Back Pain, n (%, % yes)
Neurological/Psychiatric, #
Yes, n (%)
Migraines/Headaches, n (%, % yes)
Numbness/Tingling, n (%, % yes)
Respiratory/Ears/Nose/Throat, #
Yes, n (%)
Asthma, n (%, % yes)
Sleep Apnea, n (%, % yes)
Other, #
Yes, n (%)
HIV/AIDS, n (%, % yes)

Total
70

Melatonin
35

Placebo
35

62 (88.6)

32 (91.4)

30 (85.7)

3.0 ± 3.1
0 - 18
2
1 (17)
35
23 (32.9)
20 (28.6, 87.0)
7 (10.0, 30.4)
9
9 (12.9)
7 (10.0, 77.8)
25
23 (32.9)
18 (25.7, 78.3)
10
7 (10.0)
4 (5.7, 57.1)
22
18 (25.7)
17 (24.3, 94.4)
48
31 (44.3)
10 (14.3, 32.3)
12 (17.1, 38.7)
16 (22.9, 51.6)
33
19 (27.1)
7 (10.0, 36.8)
7 (10.0, 36.8)
25
20 (28.6)
5 (7.1, 25.0)
6 (8.6, 30.0)
6
6 (8.6)
1 (1.4, 16.7)

3.6 ± 3.5
0 - 18
3
1 (8)
24
15 (42.9)
13 (37.1, 86.7)
6 (17.1, 40.0)
3
3 (8.6)
2 (5.7, 66.7)
14
13 (37.1)
10 (71.4, 76.9)
8
6 (17.1)
4 (11.4, 66.7)
11
9 (25.7)
9 (25.7, 81.8)
29
17 (48.6)
7 (20.0, 41.2)
6 (17.1, 35.3)
9 (25.7, 52.9)
21
11 (31.4)
5 (14.3, 45.5)
5 (14.3, 45.5)
12
10 (28.6)
2 (5.7, 20.0)
2 (5.7, 20.0)
3
3 (8.6)
1 (2.9, 33.3)

2.5 ± 2.4
0 - 11
2
2 (9)
11
8 (22.9)
7 (20.0, 87.5)
1 (2.9, 12.5)
6
6 (17.1)
5 (14.3, 83.3)
11
10 (28.6)
8 (22.9, 80.0)
2
1 (2.9)
0 (0.0, 0.0)
11
9 (25.7)
8 (22.9, 88.9)
19
14 (40.0)
3 (8.6, 21.4)
6 (17.1, 42.9)
7 (20.0, 50.0)
12
8 (22.9)
2 (5.7, 25.0)
2 (5.7, 25.0)
13
10 (28.6)
3 (8.6, 30.0)
4 (11.4, 40.0)
3
3 (8.6)
0 (0.0, 0.0)

% yes is defined as the number of those reporting a specific condition divided the total number reporting
a condition multiplied by 100.
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Baseline self-reported use of nicotine delivery products, consumption of caffeinated
beverages, and preferred type of exercise
Table 4 presents the self-reported use of nicotine delivery products, consumption
of caffeinated beverages, or preferred type of exercise at baseline. Sixty-three
participants (90%) reported use of nicotine delivery products with cigarettes being the
preferred mode. The vast majority (94.3%) also consumed caffeinated beverages with
coffee being preferred. The participants were physically active with about three quarters
(72.9%) of them choosing some form of exercise with lifting weights being preferred.
Statistical analyses revealed no significant differences between the two groups for the use
of nicotine delivery products, consumption of caffeinated beverages, or preferred type of
exercise
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Table 4
Self-reported Nicotine, Caffeinated Beverages, and Exercise Histories at Baseline
Variable
n
Nicotine, n (%, % yes)
Yes, n (%)

Total

Melatonin

Placebo

70

35

35

63 (90.0)

32 (91.4)

31 (88.6)

Chewing tobacco

4 (5.7, 6.3)

2 (5.7, 6.3)

2 (5.7, 6.5)

Cigarettes

56 (80.0, 88.9)

31 (88.6, 96.9)

25 (71.4, 80.6)

Snuff

12 (17.1, 19.0)

5 (14.3, 15.6)

7 (20.0, 22.6)

Vapor

0 (0.0, 0.0)

0 (0.0, 0.0)

0 (0.0, 0.0)

Caffeinated Beverages, n (%, % yes)
Yes, n (%)

66 (94.3)

33 (94.3)

33 (94.3)

Coffee

55 (78.6, 83.3)

26 (74.3, 78.8)

29 (82.9, 87.9)

Soda

35 (50.0, 53.0)

20 (57.1, 60.6)

15 (42.9, 45.5)

Tea

21 (30.0, 31.8)

10 (28.6, 30.3)

11 (31.4, 33.3)

51 (72.9)

24 (68.6)

27 (77.1)

Exercise, n (%, % yes)
Yes, n (%)
Weights

36 (51.4, 70.6)

17 (48.6, 70.8)

19 (54.3, 70.4)

Aerobics/Pilates/Yoga

10 (14.3, 19.6)

2 (5.7, 8.3)

8 (11.4, 29.6)

Running

9 (12.9, 17.6)

2 (5.7, 8.3)

7 (20.0, 25.9)

Sports

6 (8.6, 11.8)

2 (5.7, 8.3)

4 (11.4, 14.8)

Other

16 (22.3, 31.4)

7 (20.0, 29.2)

9 (25.7, 33.3)

% yes is defined as the number of those reporting a specific use divided by the total number
reporting a use multiplied by 100.
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Self-reported mental health conditions diagnosed by a medical professional
Table 5 presents the self-reported mental health histories at baseline. Ninety-one
percent (91.4%) reported a history of mental health conditions with diagnosis obtained
mostly in a hospital setting (71.9% of those reporting a diagnosis). On average, 1.9 ± 0.9
conditions were reported; specifically, 49 participants reported comorbidity of at least
two conditions accounting for 76.6% of those reporting a mental health history. Most
were diagnosed with depression followed by anxiety while 62.5% of those reporting a
mental health history were comorbid for depression and anxiety with or without other
mental health conditions. Statistical analyses revealed no significant differences between
the two groups for reported mental health history, mean number of conditions, location of
diagnosis as well as the number of participants diagnosed or comorbid.
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Table 5
Self-reported Mental Health History at Baseline
Variable

Total

Melatonin

Placebo

70

35

35

Mental Health History, n (%)
Yes

64 (91.4)

32 (91.4)

32 (91.4)

Conditions
Mean, SD

1.9 ± 0.9

1.9 ± 0.9

1.8 ± 0.9

2

2

2

n

Median
Mode, (n)

2 (32)

2 (16)

2 (16)

Diagnosis, n (%, % yes)
Anxiety

45 (64.2, 70.3)

26 (74.3, 81.3)

19 (54.3, 59.4)

Bipolar

24 (34.3, 37.5)

11 (31.4, 34.3)

13 (37.1, 40.6)

Depression

56 (80.0, 87.5)

27 (77.1, 84.4)

29 (82.9, 90.6)

5 (7.1, 7.8)

2 (5.7, 6.3)

3 (8.6, 9.4)

Comorbid, n (%, % yes)
Total (≥2 conditions)

49 (70.0, 76.6)

25 (71.4, 78.1)

24 (68.6, 75.0)

Depression & Anxiety

40 (57.1, 62.5)

22 (62.9, 68.8)

18 (51.4, 56.3)

Location, n (%, % yes)
Hospital

46 (65.7, 71.9)

22 (62.8, 68.8)

24 (68.6, 75.0)

PCP/Clinic/Rehab Center

12 (17.1, 18.8)

6 (17.1, 18.8)

6 (17.1, 18.8)

6 (8.6, 9.4)

4 (11.4, 12.5)

2 (5.7, 6.3)

Schizophrenia

Other

% yes is defined as the number of those reporting a specific diagnosis/location divided by the
total number reporting a diagnosis/location multiplied by 100.
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Self-reported illicit and non-illicit drug history at baseline
Table 6 presents the self-reported illicit and non-illicit drug histories at baseline.
On average, 2.5 ± 1.8 drugs (range of 1 -10, median 2, and mode 2). Alcohol use
(60.0%) was the most reported followed by heroin (51.4%) and crack cocaine (38.6);
however, 15.7% reported only using alcohol and 10.0% reported only using heroin. One
of the most reported multiple drug use was alcohol and cocaine or crack cocaine (27.1%).
Another popular usage was heroin and opiate drugs being reported by 20.0% of the
participants, and 17.1% reported using alcohol and heroin or opiate drugs. Statistical
analyses revealed no significant differences between the two groups for the mean number
of illicit and non-illicit drug used as well as for each illicit and non-illicit drug used.
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Table 6
Self-reported Illicit and Non-illicit Drug History
Variable

Total

Melatonin

Placebo

n
Mean, SD

70

35

35

2.5 ± 1.8

2.4 ± 1.8

2.6 ± 1.7

Range

1 - 10

1 - 10

1 - 10

Median

2

2

2

2 (29)

2 (15)

2 (14)

Illicit & Non-illicit Drugs, n (%)
Alcohol

42 (60.0)

21 (60.0)

21 (60.0)

Alcohol only

11 (15.7)

7 (20.0)

4 (11.4)

Alcohol & Cocaine or Crack Cocaine

19 (27.1)

9 (25.7)

10 (28.6)

Alcohol & Heroin or Opiate Drugs

12 (17.1)

8 (22.9)

4 (11.4)

Amphetamine

6 (8.6)

3 (8.6)

3 (8.6)

Benzodiazepines

4 (5.7)

2 (5.7)

2 (5.7)

Cocaine

16 (22.9)

5 (14.3)

11 (31.4)

Crack Cocaine

27 (38.6)

12 (34.3)

15 (42.9)

Cocaine & Crack Cocaine

10 (14.3)

5 (14.3)

5 (14.3)

2 (2.9)

1 (2.9)

1 (2.9)

Heroin

36 (51.4)

20 (57.1)

16 (45.7)

Heroin only

7 (10.0)

4 (11.4)

3 (8.6)

Heroin & Opiate Drugs

14 (20.0)

7 (20.0)

7 (20.0)

3 (4.3)

1 (2.9)

2 (5.7)

Marijuana

20 (28.6)

10 (28.6)

10 (28.6)

Marijuana & Alcohol

14 (20.0)

7 (20.0)

7 (20.0)

Marijuana & Cocaine or Crack Cocaine

14 (20.0)

6 (17.1)

8 (22.9)

1 (1.4)

1 (2.9)

0 (0.0)

17 (24.2)

8 (22.9)

9 (25.7)

2 (2.9)

1 (2.9)

1 (2.9)

Mode, (n)

Hash

LSD

MDMA
Opiate Drugs
PCP

58

Self-reported melatonin history at baseline
Table 7 presents the self-reported melatonin history at baseline. Thirty
participants (42.9%) reported a history of melatonin use with 100.0% indicating usage for
sleep. Most participants obtained the melatonin from a clinician (53.3%) most likely in a
hospital, rehabilitation center, or provided to them (46.7%). Only 40.0% could recall the
dose taken with between 3 to 10 mg being the most popular dose range. Seventy percent
of participants who reported a history believed melatonin had an effect. Most of the
participants (70.0%) reported a prior usage of greater than one month before study
enrollment. Statistical analyses revealed no significant differences between the two
groups for prior history, reason for use, motivation, place acquired, time of last use, recall
dose taken, or believed it helped.
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Table 7
Self-reported Melatonin History at Baseline
Variable

Total

Melatonin

Placebo

70

35

35

Prior History, n (%)
Yes

30 (42.9)

17 (48.6)

13 (37.1)

Reason, n (% yes)
Sleep

30 (100.0)

17 (100.0)

13 (100.0)

Motivation, n (% yes)
Clinician

16 (53.3)

11 (64.7)

5 (38.5)

Self

11 (36.7)

6 (35.3)

5 (38.5)

Both

3 (10.0)

0 (0.0)

3 (23.1)

Acquired, n (% yes)
Hospital/Rehab Center/Provided

14 (46.7)

8 (47.1)

6 (46.2)

Pharmacy

5 (16.7)

1 (5.9)

4 (30.8)

Retail

8 (26.7)

5 (29.4)

3 (23.1)

Other

1 (3.3)

1 (5.9)

0 (0.0)

Unknown/No Response

3 (10.0)

2 (11.8)

1 (7.7)

Last Use, n (% yes)
< 1 week

1 (3.3)

1 (5.9)

0 (0.0)

≤ 1 month

7 (23.3)

5 (29.4)

2 (15.4)

> 1 month to ≤ 1 year

10 (33.3)

6 (35.3)

4 (30.8)

> 1 year

11 (36.7)

5 (29.4)

6 (46.2)

Unknown/No Response

1 (3.3)

0 (0.0)

1 (7.7)

Recall Dose, n (% yes)
Yes, n (%)

n

12 (40.0)

9 (52.9)

3 (23.1)

1 mg

0 (0.0)

0 (0.0)

0 (0.0)

3 - 10 mg

10 (83.3)

8 (88.9)

2 (66.7)

>10 mg

2 (16.7)

1 (11.1)

1 (33.3)

Believe It Helped?, n (% yes)
Yes

21 (70.0)

11 (64.7)

10 (76.9)

No

5 (16.7)

4 (23.5)

1 (5.9)

Unknown/No Response

4 (13.3)

2 (11.8)

2 (15.4)
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Self-reported belief intervention taken was melatonin
Table 8 presents the self-reported belief of those who completed the 28-day study
that the intervention taken was melatonin. Twenty-one participants (43.8%) reported a
history of melatonin use. Seventeen participants (81.0%) reported that the prior use
helped. Interestingly, thirty-four participants (70.8%) believed that the intervention they
were taking was melatonin while fourteen participants (29.2%) believed it was placebo.
Fisher’s exact test revealed there was a significant difference in identified taken
intervention between the groups, p = 0.0084. Twenty-two participants (45.8%) correctly
identified the intervention they were provided while 26 participants (54.2%) were
incorrect. Moreover, 12 participants (25.0%) who incorrectly identified the provided
intervention reported a prior history of melatonin. Statistical analyses revealed no
significant differences between the two groups for prior history, prior use helped, and
belief intervention taken was melatonin.
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Table 8
Self-reported Belief Intervention taken was Melatonin
Variable

Total

Melatonin

Placebo

n (completed 28 days)

48

24

24

Prior History, n (%)
Yes

21 (43.8)

11 (45.8)

10 (41.7)

No

27 (56.3)

13 (54.2)

14 (58.3)

Prior Use Helped, n (%)
Yes

17 (81.0)

8 (72.7)

9 (90.0)

No

2 (9.5)

2 (18.2)

0 (0.0)

Unknown/No Response

2 (9.5)

1 (9.1)

1 (10.0)

Belief Intervention was Melatonin, n (%)
Yes

34 (70.8)

16 (66.7)

18 (75.0)

No

14 (29.2)

8 (33.3)

6 (25.0)

Identified Taken Intervention, n (%) **
Correct

22 (45.8)

16 (66.7)

6 (25.0)

Yes Prior History

9 (18.8)

7 (29.2)

2 (8.3)

No Prior History

13 (27.1)

9 (37.5)

4 (16.7)

26 (54.2)

8 (33.3)

18 (75.0)

Yes Prior History

12 (25.0)

4 (16.7)

8 (33.3)

No Prior History

14 (29.2)

4 (16.7)

10 (41.7)

Incorrect

Asterisks indicate significance, p < 0.05, p < 0.01, p < 0.001, and p < 0.0001
as indicated by *, **, ***, and ****, respectively.
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Self-reported adherence to interventions at 28 days (capsule count)
Table 9 presents the adherence to interventions of those who completed the 28day study. Forty-five capsule cards were returned to the investigator (CDB). On
average, 27.2 ± 1.4 capsules were taken by the participants. Specifically, forty-three
participants took the intervention as directed (i.e., 1 capsule per day); however, two
participants took more than directed. After identification, these participants were
provided an additional capsule card and again verbally given specific instructions to
administer one capsule by mouth at bedtime for the remainder of the study. Two
participants did not return the capsule card but verbally informed the investigator (CDB)
that all capsules had been taken. Statistical analyses revealed no significant differences
between the two groups for mean number of capsules taken or adherence as directed.
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Table 9
Adherence to Interventions at 28 days (Capsule Count)
Variable

Total

Melatonin

Placebo

n (completed 28 days)

48

24

24

Returned Cards, n

45

22

23

27.2 ± 1.4

27.5 ± 1.3

26.9 ± 1.5

43 (89.6)

20 (83.3)

23 (95.8)

Capsules Count
Mean, SD
Adherence, n (%)
As Directed
> Directed

2 (4.2)

2 (8.3)

0 (0.0)

Verbal Confirmation

2 (4.2)

1 (4.2)

1 (4.2)

Unknown

1 (2.1)

1 (4.2)

0 (0.0)
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Self-reported adverse events
Table 10 presents the self-reported adverse events experienced during the 28-day
study. To address any adverse events relating to the interventions, the participant was
encouraged to report any adverse events to the investigator (CDB) or at the weekly
assessments to identify any new symptoms experienced other than those at time of study
entrance. Twenty participants (28.6%) reported experiencing an adverse event. The
most reported adverse events were “fatigue/groggy/tired/sleepy,” “headache,”
“nightmares/vivid dreams,” and “sleeplessness/wakefulness.” From July to the end of
January, the investigator observed a number of individuals at the center experiencing
symptoms of the common cold; thus, the symptoms of the common cold are most likely
not attributable to the intervention. Statistical analyses revealed no significant
differences between the two groups for number of participants reporting an adverse
event.
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Table 10
Self-reported Adverse Events
Variable

Total

Melatonin

Placebo

70

35

35

20 (28.6)

13 (37.1)

7 (20.0)

Adverse Events, #
Common Cold

26

18

8

2

2

0

Diarrhea

2

0

2

Fainted

1

1

0

Fatigue/Groggy/Tired/Sleepy

6

4

2

Headache

4

2

2

Nausea

1

1

0

Nightmares/Vivid Dreams

4

4

0

Sleeplessness/Wakefulness

5

3

2

Sleep Latency

1

1

0

n
Reported, n (%)
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Intention-to-treat: mean self-reported GAD-7 scores
Figure 3 presents the mean self-reported GAD-7 scores of the melatonin and
placebo groups at baseline and each weekly assessment. Values are mean ± SEM, GAD7 scores (0 – 21). Higher scores indicate more severity of anxiety. The two-way
ANOVA was conducted to investigate score differences in intervention and time among
participants. The results revealed no significant interaction between factors (Intervention
by Time), F (4, 283) = 0.6362, p = 0.6370, ω2 = 0.7571. No significant main effect for
intervention, F (1, 283) = 0.5794, p = 0.4472, ω2 = 0.1724 was determined. However, the
two-way ANOVA results revealed a significant main effect for time, F (4, 283) = 12.51,
p < 0.0001, ω2 = 14.88. Results of the Tukey post hoc test revealed no significant
between group differences but revealed significant within group differences especially for
Baseline to Day 28 for both groups (See Table 11).
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Figure 3. The mean self-reported GAD-7 scores of the melatonin and placebo groups at baseline and each
weekly assessment. Values are mean ± SEM, GAD-7 scores (0 – 21). Higher scores indicate more severity
of anxiety. The two-way ANOVA was conducted to investigate score differences in intervention and time
among participants. The results revealed no significant interaction between factors (Intervention by Time)
and no significant main effect for intervention. However, the results revealed a significant main effect for
time. The Tukey post hoc test revealed no significant between group differences but revealed significant
within group differences especially for Baseline to Day 28 for both groups. Melatonin (n = 35) and
Placebo (n = 35).
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Intention-to-treat: mean self-reported PHQ-8 scores
Figure 4 presents the mean self-reported PHQ-8 scores of the melatonin and
placebo groups at baseline and each weekly assessment. Values are mean ± SEM, PHQ8 scores (0 – 24). Higher scores indicate more degree of depression. The two-way
ANOVA was conducted to investigate score differences in intervention and time among
participants. The results revealed no significant interaction between factors (Intervention
by Time), F (4, 283) = 0.8085, p = 0.5206, ω2 = 0.9557. No significant main effect for
intervention, F (1, 283) = 0.2558, p = 0.6134, ω2 = 0.0756 was determined. However, the
two-way ANOVA results revealed a significant main effect for time, F (4, 283) = 12.97,
p < 0.0001, ω2 = 15.34. Results of the Tukey post hoc test revealed no significant
between group differences but revealed significant within group differences especially for
Baseline to Day 28 for both groups (See Table 11).
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Figure 4. The mean self-reported PHQ-8 scores of the melatonin and placebo groups at baseline and each
weekly assessment. Values are mean ± SEM, PHQ-8 scores (0 – 24). Higher scores indicate more degree
of depression. The two-way ANOVA was conducted to investigate score differences in intervention and
time among participants. The results revealed no significant interaction between factors (Intervention by
Time) and no significant main effect for intervention. However, the results revealed a significant main
effect for time. Results of the Tukey post hoc test revealed no significant between group differences but
revealed significant within group differences especially for Baseline to Day 28 for both groups. Melatonin
(n = 35) and Placebo (n = 35).
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Intention-to-treat: mean self-reported PSS-14 scores
Figure 5 presents the mean self-reported PSS-14 scores of the melatonin and
placebo groups at baseline and each weekly assessment. Values are mean ± SEM, PSS14 scores (0 – 56). Higher scores indicate more degree of stress. The two-way ANOVA
was conducted to investigate score differences in intervention and time among
participants. The results revealed no significant interaction between factors (Intervention
by Time), F (4, 283) = 0.3180, p = 0.8658, ω2 = 0.3666. No significant main effect for
intervention, F (1, 283) = 0.5188, p = 0.4719, ω2 = 0.1495 was determined. However, the
two-way ANOVA results revealed a significant main effect for time, F (4, 283) = 15.54,
p < 0.0001, ω2 = 17.92. Results of the Tukey post hoc test revealed no significant
between group differences but revealed significant within group differences especially for
Baseline to Day 28 for both groups (See Table 11).
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Figure 5. The mean self-reported PSS-14 scores of the melatonin and placebo groups at baseline and each
weekly assessment. Values are mean ± SEM, PSS-14 scores (0 – 56). Higher scores indicate more degree
of stress. The two-way ANOVA was conducted to investigate score differences in intervention and time
among participants. The results revealed no significant interaction between factors (Intervention by Time)
and no significant main effect for intervention. However, the results revealed a significant main effect for
time. Results of the Tukey post hoc test revealed no significant between group differences but revealed
significant within group differences especially for Baseline to Day 28 for both groups. Melatonin (n = 35)
and Placebo (n = 35).
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Intention-to-treat: mean self-reported PSSQ-1 sleep complaints scores
Figure 6 presents the mean self-reported PSSQ-1 sleep complaints scores of the
melatonin and placebo groups at baseline and each weekly assessment. Values are mean
± SEM, PSSQ-1 scores (0 – 25). Higher scores indicate more frequency of sleep
complaints. The two-way ANOVA was conducted to investigate score differences in
intervention and time among participants. The results revealed no significant interaction
between factors (Intervention by Time), F (4, 283) = 0.3877, p = 0.8174, ω2 = 0.5059.
No significant main effect for intervention, F (1, 283) = 0.5397, p = 0.4632, ω2 = 0.1761
was determined. However, the two-way ANOVA results revealed a significant main
effect for time, F (4, 283) = 5.359, p < 0.0004, ω2 = 6.993. Results of the Tukey post hoc
test revealed no significant between group differences but revealed a significant within
group difference for Baseline to Day 28 for only the melatonin group (See Table 11).
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Figure 6. The mean self-reported PSSQ-1 sleep complaint scores of the melatonin and placebo groups at
baseline and each weekly assessment. Values are mean ± SEM, PSSQ-1 scores (0 – 25). Higher scores
indicate more frequency of sleep complaints. The two-way ANOVA was conducted to investigate score
differences in intervention and time among participants. The results revealed no significant interaction
between factors (Intervention by Time) and no significant main effect for intervention. However, the
results revealed a significant main effect for time. Results of the Tukey post hoc test revealed no
significant between group differences but revealed a significant within group difference for Baseline to Day
28 for only the melatonin group. Melatonin (n = 35) and Placebo (n = 35).
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Intention-to-treat: mean self-reported PSSQ-1 sleep affecting daily life scores
Figure 7 presents the mean self-reported PSSQ-1 sleep affecting daily life scores
of the melatonin and placebo groups at baseline and each weekly assessment. Values are
mean ± SEM, PSSQ-1 scores (0 – 32). Higher scores indicate more effect on daily life.
The two-way ANOVA was conducted to investigate score differences in intervention and
time among participants. The results revealed no significant interaction between factors
(Intervention by Time), F (4, 283) = 0.3946, p = 0.8124, ω2 = 0.4941. No significant
main effect for intervention, F (1, 283) = 0.02420, p = 0.8765, ω2 = 0.007574 was
determined. However, the two-way ANOVA results revealed a significant main effect
for time, F (4, 283) = 8.713, p < 0.0001, ω2 = 10.91. Results of the Tukey post hoc test
revealed no significant between group differences but revealed a significant within group
difference for Baseline to Day 28 for only the melatonin group (See Table 11).
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Figure 7. The mean self-reported PSSQ-1 sleep affecting daily life scores of the melatonin and placebo
groups at baseline and each weekly assessment. Values are mean ± SEM, PSSQ-1 scores (0 – 32). Higher
scores indicate more effect on daily life. The two-way ANOVA was conducted to investigate score
differences in intervention and time among participants. The results revealed no significant interaction
between factors (Intervention by Time) and no significant main effect for intervention. However, the
results revealed a significant main effect for time. Results of the Tukey post hoc test revealed no
significant between group differences but revealed a significant within group difference for Baseline to Day
28 for only the melatonin group. Melatonin (n = 35) and Placebo (n = 35).
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Complete case: mean self-reported GAD-7 scores
Figure 8 presents the mean self-reported GAD-7 scores of the melatonin and
placebo groups at baseline and each weekly assessment. Values are mean ± SEM, GAD7 scores (0 – 21). Higher scores indicate more severity of anxiety. The two-way
ANOVA was conducted to investigate score differences in intervention and time among
participants. The results revealed no significant interaction between factors (Intervention
by Time), F (4, 230) = 0.3903, p = 0.8155, ω2 = 0.5176. No significant main effect for
intervention, F (1, 230) = 2.394, p = 0.1231, ω2 = 0.7939 was determined. However, the
two-way ANOVA results revealed a significant main effect for time, F (4, 230) = 16.91,
p < 0.0001, ω2 = 22.43. Results of the Tukey post hoc test revealed no significant
between group differences but revealed significant within group differences especially for
Baseline to Day 28 for both groups (See Table 11).
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Figure 8. The mean self-reported GAD-7 scores of the melatonin and placebo groups at baseline and each
weekly assessment. Values are mean ± SEM, GAD-7 scores (0 – 21). Higher scores indicate more severity
of anxiety. The two-way ANOVA was conducted to investigate score differences in intervention and time
among participants. The results revealed no significant interaction between factors (Intervention by Time)
and no significant main effect for intervention. However, the results revealed a significant main effect for
time. The Tukey post hoc test revealed no significant between group differences but revealed significant
within group differences especially for Baseline to Day 28 for both groups. Melatonin (n = 24) and
Placebo (n = 24).
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Complete case: mean self-reported PHQ-8 scores
Figure 9 presents the mean self-reported PHQ-8 scores of the melatonin and
placebo groups at baseline and each weekly assessment. Values are mean ± SEM, PHQ8 scores (0 – 24). Higher scores indicate more degree of depression. The two-way
ANOVA was conducted to investigate score differences in intervention and time among
participants. The results revealed no significant interaction between factors (Intervention
by Time), F (4, 230) = 0.3410, p = 0.8501, ω2 = 0.4588. No significant main effect for
intervention, F (1, 230) = 1.311, p = 0.2534, ω2 = 0.4409 was determined. However, the
two-way ANOVA results revealed a significant main effect for time, F (4, 230) = 16.16,
p < 0.0001, ω2 = 21.74. Results of the Tukey post hoc test revealed no significant
between group differences but revealed significant within group differences especially for
Baseline to Day 28 for both groups (See Table 11).

79

Figure 9. The mean self-reported PHQ-8 scores of the melatonin and placebo groups at baseline and each
weekly assessment. Values are mean ± SEM, PHQ-8 scores (0 – 24). Higher scores indicate more degree
of depression. The two-way ANOVA was conducted to investigate score differences in intervention and
time among participants. The results revealed no significant interaction between factors (Intervention by
Time) and no significant main effect for intervention. However, the results revealed a significant main
effect for time. Results of the Tukey post hoc test revealed no significant between group differences but
revealed significant within group differences especially for Baseline to Day 28 for both groups. Melatonin
(n = 24) and Placebo (n = 24).
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Complete case: mean self-reported PSS-14 scores
Figure 10 presents the mean self-reported PSS-14 scores of the melatonin and
placebo groups at baseline and each weekly assessment. Values are mean ± SEM, PSS14 scores (0 – 56). Higher scores indicate more degree of stress. The two-way ANOVA
was conducted to investigate score differences in intervention and time among
participants. The results revealed no significant interaction between factors (Intervention
by Time), F (4, 230) = 0.2534, p = 0.9074, ω2 = 0.3395. No significant main effect for
intervention, F (1, 230) = 0.6704, p = 0.4137, ω2 = 0.2246 was determined. However, the
two-way ANOVA results revealed a significant main effect for time, F (4, 283) = 16.71,
p < 0.0001, ω2 = 22.39. Results of the Tukey post hoc test revealed no significant
between group differences but revealed significant within group differences especially for
Baseline to Day 28 for both groups (See Table 11).
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Figure 10. The mean self-reported PSS-14 scores of the melatonin and placebo groups at baseline and
each weekly assessment. Values are mean ± SEM, PSS-14 scores (0 – 56). Higher scores indicate more
degree of stress. The two-way ANOVA was conducted to investigate score differences in intervention and
time among participants. The results revealed no significant interaction between factors (Intervention by
Time) and no significant main effect for intervention. However, the results revealed a significant main
effect for time. Results of the Tukey post hoc test revealed no significant between group differences but
revealed significant within group differences especially for Baseline to Day 28 for both groups. Melatonin
(n = 24) and Placebo (n = 24).
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Complete case: mean self-reported PSSQ-1 sleep complaints scores
Figure 11 presents the mean self-reported PSSQ-1 sleep complaints scores of the
melatonin and placebo groups at baseline and each weekly assessment. Values are mean
± SEM, PSSQ-1 scores (0 – 25). Higher scores indicate more frequency of sleep
complaints. The two-way ANOVA was conducted to investigate score differences in
intervention and time among participants. The results revealed no significant interaction
between factors (Intervention by Time), F (4, 230) = 0.2352, p = 0.9183, ω2 = 0.3624. A
significant main effect for intervention, F (1, 230) = 5.817, p = 0.0167, ω2 = 2.241 was
determined. Also, the two-way ANOVA results revealed a significant main effect for
time, F (4, 230) = 5.703, p = 0.0002, ω2 = 8.788. Results of the Tukey post hoc test
revealed no significant between group differences and no significant within group
differences especially for Baseline to Day 28 for both groups (See Table 11).
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Figure 11. The mean self-reported PSSQ-1 sleep complaint scores of the melatonin and placebo groups at
baseline and each weekly assessment. Values are mean ± SEM, PSSQ-1 scores (0 – 25). Higher scores
indicate more frequency of sleep complaints. The two-way ANOVA was conducted to investigate score
differences in intervention and time among participants. The results revealed no significant interaction
between factors (Intervention by Time) but a significant main effect for intervention. Also, the results
revealed a significant main effect for time. Results of the Tukey post hoc test revealed no significant
between group differences and no significant within group differences for Baseline to Day 28 for the
groups. Melatonin (n = 24) and Placebo (n = 24).
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Complete case: mean self-reported PSSQ-1 sleep affecting daily life scores
Figure 12 presents the mean self-reported PSSQ-1 sleep affecting daily life
scores of the melatonin and placebo groups at baseline and each weekly assessment.
Values are mean ± SEM, PSSQ-1 scores (0 – 32). Higher scores indicate more effect on
daily life. The two-way ANOVA was conducted to investigate score differences in
intervention and time among participants. The results revealed no significant interaction
between factors (Intervention by Time), F (4, 230) = 0.3359, p = 0.8536, ω2 = 0.4712.
No significant main effect for intervention, F (1, 230) = 1.891, p = 0.1704, ω2 = 0.6631
was determined. However, the two-way ANOVA results revealed a significant main
effect for time, F (4, 230) = 12.99, p < 0.0001, ω2 = 18.22. Results of the Tukey post hoc
test revealed no significant between group differences but revealed significant within
group differences especially for Baseline to Day 28 for both groups (See Table 11).
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Figure 12. The mean self-reported PSSQ-1 sleep affecting daily life scores of the melatonin and placebo
groups at baseline and each weekly assessment. Values are mean ± SEM, PSSQ-1 scores (0 – 32). Higher
scores indicate more effect on daily life. The two-way ANOVA was conducted to investigate score
differences in intervention and time among participants. The results revealed no significant interaction
between factors (Intervention by Time) and no significant main effect for intervention. However, the
results revealed a significant main effect for time. Results of the Tukey post hoc test revealed no
significant between group differences but revealed significant within group differences especially for
Baseline to Day 28 for both groups. Melatonin (n = 24) and Placebo (n = 24).
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Mean difference and percent change from baseline to day 28
Table 11 presents the mean difference and percent change from Baseline to Day
28 of each outcome measure of the interventions. Values are mean difference (95%
confidence interval) with significance indicated by asterisks.
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Table 11
Mean Difference and Percent Change from Baseline to Day 28
Outcome Measure

Melatonin

Placebo

Day 28 ± SEM

10.37143 ± 0.835238
3.375 ± 0.711735

9.742857 ± 0.938748
4.833333 ± 0.926006

Mean Difference

6.996 (2.935, 11.06)****

4.910 (0.8483, 8.971)**

% Change

67.46

50.39

Day 28 ± SEM

10.33333 ± 0.795432
3.375 ± 0.711735

10.54167 ± 0.970342
4.833333 ± 0.926006

Mean Difference

6.958 (3.111, 10.81)****

5.708 (1.861, 9.556)***

% Change

67.33

54.15

10.74286 ± 0.833483

Day 28 ± SEM

11.77143 ± 0.914942
4.75 ± 0.984021

Mean Difference

7.021 (2.844, 11.20)****

5.201 (1.023, 9.379)**

% Change

59.65

48.42

Day 28 ± SEM

11.41667 ± 0.948247
4.75 ± 0.984021

5.541667 ± 0.947879

Mean Difference

6.667 (2.559, 10.77)****

6.333 (2.225, 10.44)****

% Change

58.39

53.33

30.05714 ± 1.252857

Day 28 ± SEM

31.85714 ± 1.207221
21.29167 ± 1.594237

Mean Difference

10.57 (4.172, 16.96)****

8.849 (2.455, 15.24)***

% Change

33.17

29.44
30.41667 ± 1.27656

Day 28 ± SEM

31.79167 ± 1.200392
21.29167 ± 1.594237

Mean Difference

10.50 (4.101, 16.90)****

9.208 (2.810, 15.61)***

% Change

33.03

30.27

15.4 ± 1.118372

Day 28 ± SEM

16.57143 ± 1.031671
10.08333 ± 1.490206

11.79167 ± 1.220268

Mean Difference

6.488 (0.7428, 12.23)*

3.608 (-2.137, 9.354)

% Change

39.15

23.43

GAD-7
ITT
Baseline ± SEM

CC
Baseline ± SEM

PHQ-8
ITT
Baseline ± SEM

CC
Baseline ± SEM

PSS-14
ITT
Baseline ± SEM

CC
Baseline ± SEM

5.541667 ± 0.947879

11.875 ± 0.788603

21.20833 ± 1.91578

21.20833 ± 1.91578

PSSQ-1
Sleep Complaints
ITT
Baseline ± SEM
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CC
Baseline ± SEM
Day 28 ± SEM

15.45833 ± 1.066694
10.08333 ± 1.490206

16.41667 ± 0.99429
11.79167 ± 1.220268

Mean Difference

5.375 (-0.1545, 10.90)

4.625 (-0.9045, 10.15)

% Change

34.77

28.17

14.4 ± 1.394587

Day 28 ± SEM

16.00 ± 1.32589
7.916667 ± 1.510731

8.625 ± 1.466797

Mean Difference

8.083 (1.735, 14.43)**

5.775 (-0.5736, 12.12)

% Change

50.52

40.10

15.95833 ± 1.288727
7.916667 ± 1.510731

15.75 ± 1.234343

Day 28 ± SEM
Mean Difference

8.042 (2.110, 13.97)***

7.125 (1.194, 13.06)**

% Change

50.39

45.24

Quality of life
ITT
Baseline ± SEM

CC
Baseline ± SEM

8.625 ± 1.466797

Mean difference (Baseline - Day 28).
Percent change [(Baseline - Day 28) / Baseline] * 100
Values in parentheses are 95% confidence interval.
ITT = Intention-to-treat; CC = Complete case
Asterisks indicate significance, p < 0.05, p < 0.01, p < 0.001, and p < 0.0001
as indicated by *, **, ***, and ****, respectively.
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Contingency table analysis and strength of association
Table 12 presents the results of the Fisher’s exact test (two-tailed, CI 95%) and
the strength of association reported as relative risk (95% CI) of the change following the
intervention. No significant differences were detected. All confidence intervals of the
strength of association included the null value of 1, thus concluding there exists
insufficient evidence to suggest that the interventions were significantly different.
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Table 12
Contingency Table Analysis and Strength of Association
Outcome
Measure
P value
Relative Risk (95% CI)
GAD-7

1.0000

1.063 (0.6466 to 1.746)

PHQ-8

0.6279

1.231 (0.7014 to 2.160)

PSS-14

0.5401

0.6250 (0.2260 to 1.724)

PSSQ-1
Complaints

0.5613

1.500 (0.5973 to 3.767)

Daily life

0.7972

1.200 (0.5980 to 2.408)
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DISCUSSION
Based upon the results of the systematic review, three identified studies
investigated the use of melatonin in those recovering from alcohol dependency. All three
studies investigated the effect of melatonin on sleep measures while only one study
included assessments of its antidepressant and anxiolytic effects. Therefore, clinical
investigations into the use of melatonin as a treatment for depression, anxiety, stress, and
sleep difficulties in those recovering from illicit and non-illicit drug dependency is
limited and more studies are warranted. This is the first and largest randomized, doubleblind, placebo-controlled trial assessing the effects of melatonin upon post-acute
withdrawal among males in a residential treatment program. The purpose of the study
was to assess the effect of 5 mg melatonin compared to placebo as an adjuvant treatment
along with their current pharmaco- and behavioral therapies for 28 days on weekly selfreported severity of anxiety, depression, stress, and sleep complaints as well as how sleep
is affecting daily life in a sample of males in recovery from chemical dependency at a
single, residential treatment site.
Even though the results for all outcome measures revealed statistically significant
within-groups differences over time for both groups, post hoc analyses revealed the study
lacked sufficient evidence to demonstrate statistically significant between-group
differences for these measures. Additionally, contingency table analysis as well as the
relative degree of association between response for participants who are taking melatonin
compared to those taking placebo (i.e., relative risk) revealed no significant strength of
association between the groups (i.e., confidence interval included null value of 1) when
considering worst case for the loss to follow-up. Overall, the various analyses indicated
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there exists insufficient evidence to suggest that melatonin and placebo were significantly
different, and it may be concluded, based upon the study sample, design, and its
limitations, the effect of melatonin on the assessed measures was no different than
placebo.
The mean age of the sample was 40.4 ± 11 years (range 21 – 65 and median 39)
and consisted mostly of those who identified as white (70%), single (74.3%), and with an
education level of high school/G.E.D. or less (77.1%). Black/African-American
enrollment was at 24.3%. The sample was similar to the racial demographics reported in
the Treatment Episode Data Set (TEDS) of nationwide admissions into substance abuse
treatment facilities where it was reported that Whites and African-Americans account for
60% and 21%, respectively (9). The participants have a variety of medical issues with
88.6% reporting a medical condition and also present with multiple medication use with
an average of 3.5 ± 2.2 (range 0 – 11 and median 3) medications. Interestingly, a total of
75 different medications were prescribed including antiviral (HIV/AIDS), cardiovascular,
central nervous, endocrine, gastrointestinal, respiratory, nutraceuticals (i.e., vitamins,
minerals, and nutritional supplements), and other medications with 157 total medications
being prescribed for treating conditions of the central nervous system. Collectively, the
histories suggest that these individuals experience a tremendous burden of neurological
disorders such as cervical or lumbar disc radiculopathies and mood disorders. As
detailed, 91.4% reported a history of diagnosed mental health conditions. Of those
reported, depression followed by anxiety were the most reported with 62.5% reporting
co-occurring depression and anxiety with or without other mental health conditions. The
prevalence of mental health issues is substantially higher in the study sample compared to
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the U.S. general population. This difference may be due to the lack of psychiatric
services for the population at the center resulting in over diagnosis by non-psychiatric
physicians. As stated in 2013 NSDUH report, 3.2% of adults had both a substance use
disorder and any mental illness and 1% of adults had both a substance use disorder and a
serious mental illness (5). Of interest, 24.3% of participants reported a history of
hepatitis. However, based upon the expected medication usage for the 28 days, no
medications specific to hepatitis treatment were reported. Unfortunately, the study did
not investigate if these participants had undergone treatment in the past or were expecting
to be treated in the future.
To add to their future health and medical burden, 90% of the participants reported
use of nicotine delivery products with cigarettes being the most favored. Caffeinated
beverage consumption was high with coffee being preferred. Of note, the center had a
coffee maker, tea packets, and soda dispensing machine available for resident use. It may
be surmised that the residents are substituting or maintaining use of more socially
acceptable stimulants (nicotine and caffeine) while trying to remain abstinent from much
harder drugs. Regarding fitness activities, about three quarters of the participants did
some form of exercise during the week with weight training being the most preferred.
One reason for such a high use is the availability of an onsite recreation room that housed
weight training equipment.
Regarding chemical dependency, the participants reported a history of multiple
illicit and non-illicit drug use. The most frequently reported number of drugs used was
two with a history of alcohol use being the most prevalent (60%); specifically 15.7%
reported abuse of alcohol only while 44.3% abused alcohol and another drug; these
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findings vary from the TEDS report that stated 41.4% of admissions sought treatment for
alcohol abuse (23.1% alchohol only) and 18.3% of those for abusing alcohol with another
drug. Reported stimulant abuse was higher than the TEDS reported findings of 17.8% for
cocaine and other stimulants. In line with the TEDS report of 20% of those seeking
treatment sought treatment for heroin and other opiates, 20% of the sample reported a
history of abuse of heroin and opiate drugs.
History of prior melatonin use was surveyed to investigate if more participants
were willing to participate that may have had a positive experience of use, in contrast to
those not willing to participate who may have had an adverse experience. As reported,
almost half of the sample (42.9%) indicated prior use with 100% using it for treating their
sleep difficulties, and 70.0% believed it helped. Overall, about 30.0% out of all the
participants had a favorable opinion of melatonin at study entrance. Even though it is
readily available on store shelves, over half of the participants (53.3%) received
melatonin from a clinician mostly in a hospital or rehabilitation center at reported doses
of 3 to 10 mg. Interestingly, although there is a body of evidence that suggests that
melatonin is efficacious for sleep, there is a paucity of evidence-based literature of its
efficacy in this population.
Even though it is difficult to specifically ascertain issues with study masking or
efficacy of the intervention, the belief of the participant completing 28 days regarding
intervention allocation was assessed by asking “Do you believe you were taking
melatonin?” The rationale for the inquiry was because 30.0% of the participants had a
positive prior melatonin experience and may have remained cognizant of its effects.
Surprisingly, thirty-four participants (70.8%) believed the assigned intervention taken
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was melatonin. To provide more evidence of their belief, most of the returned capsule
cards were missing the two extra provided capsules suggesting the participants kept the
capsules. Because of the high percentage of participants believing the assigned
intervention taken was melatonin, twenty-two participants (45.8%) correctly identified
the intervention while 26 participants (54.2%) were incorrect. Interestingly, 12
participants (25.0%) who incorrectly identified the provided intervention reported a prior
history of melatonin use. It would seem that a prior history of use would suggest the
ability to recall similarities between the previous effect and the current effect; however
this appeared to not be the case.
Although adherence, as determined by capsule counts, was very high, questions
about the true adherence remain. For example, one individual was assessed to Day 21
but left the center, and the capsule card located in the room was untouched. Potentially,
this capsule card could have been returned to the investigator devoid of capsules by
disposing of the capsules before entering the designated room for Day 28 assessment.
Also, the nightly administration of the capsules was the responsibility of the participant
and no direct observation of capsule administration by staff or investigators was
conducted.
To assess for adverse events, the participants were prompted to report any new
symptoms during the past week; however, because of the nature of the participants, they
may have underreported events out of the unfounded fear of being withdrawn from the
study or being accustomed to not revealing too much information (i.e., incriminate
oneself) suggesting a potential reporting bias. Overall, the adverse events were similar
between the interventions except for a tendency of melatonin to induce more
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nightmares/vivid dreams and next day fatigue/grogginess which are commonly associated
with melatonin use. One reason for the increase in next day effects may be attributed to a
lack of established bedtime by the study or the center. Therefore, the experimental
intervention may have been taken later in the night; thus, the 5 mg dose may have
resulted in a carryover effect to late morning. Importantly, melatonin levels are
influenced by various classes of drugs (e.g., psychotropic medications) that induce,
inhibit, or act as a substrate of CYP1A2 (42). Thus, there exists the possibility that the
prescribed medications may have affected the metabolism of melatonin. Even though
majority of participants had prior history of melatonin use, they expressed a keen interest
and concern about the potential adverse events associated with melatonin, and its
potential impact in their recovery.
Both groups resulted in a rapid improvement in measured outcomes from
Baseline to Day 28 with the sharpest improvement occurring from Baseline to Day 7.
This improvement may be attributed to the individual being in a stable, supportive
environment, having access to necessary resources, as well as being provided pharmacoand behavioral therapies. Because the study incorporated weekly measures in an effort to
allow for a detection of an effect of melatonin on a weekly basis instead of at the final
endpoint of 28 days, the impact of the effect of melatonin compared to placebo on
measured outcomes at each weekly assessment was further investigated by conducting
two-way ANOVA (Intervention by Outcome) with the complete cases. In aggregate, no
between-group differences were detected (Data not shown). To further support the
results of the intention-to-treat analyses as well as to assure that the sample of those
completing the study were similar in outcomes (i.e., results not affected by loss to follow-
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up), complete case analyses with two-way ANOVA (Intervention by Time) for all
outcomes were also performed. Overall, both the intention-to-treat and complete case
analyses generated similar results (i.e., no between group differences for all outcomes).
Additionally, the proportion of those having a response for each group revealed no
significant strength of association between the groups (i.e., confidence interval included
null value of 1) considering worst case for the loss to follow-up.
Limitations and generalizability
Because the study was conducted at the Salvation Army Harbor Light Center in
Pittsburgh, PA, it was not a multicenter study but a single center study, and the center has
a unique approach to treatment where men are cared for physically, mentally, and
spiritually in order to allow each man to realize his worth, value, and personhood. Also,
the study was age, gender, and geographically restricted to males over the age of 18 who
are residents of Allegheny County with a valid Pennsylvania identification; thus
investigations into the effects in adolescents, females, or those residing outside of
Allegheny County were not possible. Because sampling and enrollment occurred from
July 2015 to December 2015, there existed the potential that time of year may have
influenced endogenous melatonin duration of action because research has shown that
duration of action of endogenous melatonin is affected by the season due to variation in
light exposure (32). Thus, future studies may want to consider limiting enrollment to one
season. Most of the participants in the study were enrolled within a week to two weeks
upon entrance into the center. Thus, there exists the possibility that some of the
participants may have been still experiencing the acute phase of withdrawal instead of
being in post-acute withdrawal. Unfortunately, the study did not include assessment of
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levels of melatonin thus limiting the knowledge of levels of melatonin in the participants
at inclusion and upon completion of study. If levels of melatonin were assessed, for
example at each follow-up, then a correlation between the levels of melatonin to outcome
could be performed. Additionally, the data obtained from assessing levels of melatonin
could be used to provide insight into why participants responded or not. Also, the levels
would provide additional data for intervention adherence along with the capsule counts.
The inclusion and exclusion criteria in the study was broad and did not limit eligibility
for type of chemical dependency, mental health status, prescribed medication (e.g.,
antidepressant, anxiolytic, and/or sedating psychotropic drugs), prior melatonin use,
and/or medical conditions. Once accepted into the center, the residents follow a daily
schedule that includes group and individual therapy sessions, meals, and activities.
However, it must be emphasized that individuals at the center are heterogeneous and
present with a complex history of chemical dependency along with potentially cooccurring mental health and medical conditions, limited formal education, societal issues,
the episodic nature of symptoms of PAWS, and multiple medication use that adds to the
difficulty of studying the effect of melatonin on the measured outcomes. Even though
the outcomes measured were conducted with readily available, brief, and valid
instruments, a few individuals had requested help during survey completion; thus, more
individuals may have had needed help but were self-conscious as not to inquire for help.
As aforementioned, the instruments used are valid and reliable for measuring selfreported psychiatric symptoms, the literature reporting the validity and reliability in use
with a population in recovery is limited thus adding difficulty of generalizability to this
population (74, 75). Any one of these could potentially impact the outcomes (i.e.,
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improvement) thereby reducing between-group differences or the potential therapeutic
effect of melatonin leading to a possible Type II error, failure to reject the null hypothesis
(i.e., accepting the null hypothesis) that is false. Group algorithms and subsequent
subgroup analyses were not conducted because of the lack of significant between-group
differences as well as the limited sample number thereby these analyses would have been
underpowered.
In retrospect, the study would have been aided by the inclusion of a therapy alone
arm to assess the effects of therapy alone without the adjuvant addition of the
interventions. The milieu of a total therapeutic environment may have accounted for the
decrease observed in the measured outcomes independent of the effect of treatment or
placebo. While reading the consent form, the participants were informed of the
likelihood of being assigned to either the melatonin or placebo group potentially biasing
the perception of intervention assignment and the outcomes. Because of the high
percentage of belief the intervention taken was melatonin, the participants may have had
or developed through further research during participation, ideas of the efficacy and value
of melatonin as a treatment. Moreover, spillover effect may have occurred because
participants had the potential to freely discuss the effects of the interventions among their
fellow residents potentially biasing their perception of efficacy. From observation, the
participants were actively aware of the pharmacology and adverse events associated with
their prescribed pharmacotherapies. Because of the overall residential and rehabilitative
environment of the center as well as the various types of support provided by it, there
exists the possibility that participants may be motivated to demonstrate improvement in
symptoms over time to maintain residency at the center. This would bias the results by
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falsely demonstrating an improvement over time as well as masking any true effect of the
experimental intervention, if one exists.
It is difficult to assess the impact of the psychotropic medications on the
measured outcomes because the study lacked questions addressing medication indication
(e.g., sleep versus mood disorders) and the length of time the individual has been taking
the medication. Although the participant histories form asked for current medication and
its dosage regimen, it was difficult for a few individuals to recall the list of prescribed
medications as well as the dosage regimen. Considering medications such as
antidepressants may take weeks before therapeutic effect is observed, there is uncertainty
as to duration of therapy and their adherence. The improvement in outcome measures
may be result of the efficacy of psychotropic medications thereby reducing betweengroup differences and/or potentially attenuated or masked the effect of melatonin, if any.
Another possibility is that the efficacy is similar between melatonin and psychotropic
medications, and the generated data did not suggest a potentiating effect with
concomitant use.
The outcomes were measured weekly (Monday or Thursday) and was based on
day of enrollment. Analysis revealed no between-group differences comparing those
surveyed on Monday or Thursday (Data not shown). Importantly, each designated time
frame indicated on the surveys was changed to “over the last seven days” for the followup times. This change was implemented to alleviate the influence of recall bias. Because
the individuals were assessed with subjective, self-reported measures, there is the
potential for recall bias. For example, the individuals may be more acutely aware of how
they were feeling on those days closer to the assessment than earlier days. Moreover,
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their physical and mental state may have influenced their ability to recall, thus biasing the
subjective measures. Self-reported measures, in part, rely on the subjective experiences
of the participant and as such bring into question the reliability of such measures. No
objective measures were conducted to complement the self-reported measures especially
using physiological measures; specifically for example, assessment of sleep with
polysomnography, which would have been not feasible at the center, or wrist actigraphy.
Thus, no correlations between subjective and objective measures were able to be
performed to determine accuracy of the self-reported measures.
Because the participant histories as well as the self-reported outcome measures
may not have been completed accurately, the collected data is susceptible to recall bias as
well as the mood or willingness/openness of the participant to provide accurate
information, and as such, questions remain as to the reliability and validity of the data.
However, no significant between-group differences were detected for all outcome
measures suggesting that any bias with regards to accuracy were similar. Also, interindividual variability in the outcome measures may affect the detection of between-group
differences. Although underpowered, no between-group differences were detected after
conducting additional analyses, excluding those participants with either mild anxiety or
depression (Data not shown). A deeper investigation into how the high belief that the
intervention taken was melatonin may have influenced the results is warranted.
As aforementioned, previous literature investigating the use of melatonin is
limited and suffers from either lack of placebo control, small sample size, or sample
consisting of only abstinent alcohol dependent individuals. Because of the limited data,
the power analysis was calculated with a small effect size in order to enroll a larger
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number of individuals to allow for adequate power to capture a small melatonin effect (>
0.15). Conversely, if larger effect sizes were selected, the number of individuals needed
to be enrolled would have been less. Even though there were no significant betweengroup differences, the mean differences from Baseline to Day 28 of the melatonin group
were larger for all outcomes compared to placebo suggesting a potential very small effect
of melatonin that may be detectable with a larger “n.”
The study lacked a run-in period to help address if exclusions needed to be made;
for example, participants not adhering to prescribed medications, potential to disregard
study protocol, or at a high risk for loss to follow-up. Even though the power analysis
included an adjustment for a predicted loss to follow-up of <20%, the loss to follow-up
was 31.4% suggesting the study may be slightly underpowered. Based upon the returned
probability values, none of the between-group comparisons closely trended toward
statistical significance. Coincidentally, both groups had the same loss to follow-up. The
rate of loss to follow-up was consistent throughout the weeks with the highest occurring
between Day 14 and Day 21 for both groups. Loss to follow-up due to drug relapse was
the highest at 45.5% suggesting the increased difficulty in maintaining abstinent even
being in a supportive environment and provided needed resources. Those that relapsed
were detected to be under the influence of alcohol, benzodiazepines, heroin, or opiates.
Two participants relapsed on benzodiazepines. Strikingly, only four participants selfreported benzodiazepine history. The reason may be attributed to the patient history not
directing addressing benzodiazepine use but indirectly through the term “Other.” Of
those who relapsed, a higher prevalence of heroin, opiates, and marijuana usage, but
lower usage of alcohol was reported compared to the sample. Also, mental health
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disorders such as anxiety, bipolar as well as being comorbid for ≥2 were more prevalent.
Another factor contributing to the loss to follow-up was administrative rule/policy
violations possibly due to the center having a close to zero tolerance approach to
violations. Melatonin and placebo appeared to be well tolerated and each group had only
one individual withdrawing due to an adverse event. The individual lost to follow-up due
to adherence with intervention is the same individual who was determined to not be
taking the study intervention after discovery of the full capsule card upon leaving the
center shortly after completing Day 21. Only the Baseline data was included in the
analyses. Unfortunately, one individual who was out on a weekend pass given by the
center was discovered deceased on a street in Pittsburgh. The event leading to cause of
death was still under investigation at time of study conclusion, but it was suggested that it
was a possible drug overdose. Because of the ambiguity, loss to follow-up was recorded
as “Death” but not “Relapse.” It is unlikely that melatonin may have influenced the
potential drug relapse leading to death or death, in general. Relapse rates were the same
between the interventions, and melatonin has a high margin of safety. Block
randomization with a block size of four was utilized to ensure equal treatment allocation,
but a larger block size could have been used to ensure greater unpredictability as to
treatment allocation.
Positively, the study met the recruitment and eligibility goal of 70 individuals in a
time frame of six months. Unfortunately, a motivating factor may have been the weekly
financial compensation. These individuals enrolled at the center tended to be of lower
socioeconomic status and without current earning power (i.e., without a source of
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income). Therefore, enrollment in the study provided access to funds that allowed them
to purchase items such as cigarettes, an unintended consequence.
Future directions
Possible future directions include a study design that is multicenter, the inclusion
of a therapy only arm, assessing various doses and timelines, assessing effects in
adolescents or females, assessing levels of melatonin at inclusion and study completion,
assessing nocturnal levels of melatonin, or limiting inclusion based on prescribed
medications, mental health status, medical conditions, prior melatonin use, and/or a
specific chemical dependency. Additionally, more clearly defined medication histories
could be considered when enrolling participants. Future studies may incorporate a
protocol that ensures participants are actively taking the intervention nightly as well as
consider establishing a specified bedtime range. If the effect of melatonin is indeed very
small, future studies should enroll a larger sample. Also, it is recommended that a future
power analysis include adjusting for at least a loss to follow-up greater than 30%.
Because of the loss to follow-up was the highest between Day 14 and Day 21 for both
groups, a study design considering a run-in may want to include a run-in length of at least
two weeks.
Conclusions
Based upon the review of the literature, this is the first and largest randomized,
double-blind, placebo-controlled trial assessing the effects of melatonin upon post-acute
withdrawal among males in a residential treatment program. The purpose of the study
was to assess melatonin as an adjuvant treatment along with their current pharmaco- and
behavioral therapy for 28 days on weekly self-reported severity of anxiety, depression,
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stress, and sleep complaints as well as how sleep is affecting daily life in a sample of
individuals in recovery from chemical dependency at a single, residential treatment site.
In summary, the various analyses indicated there exists insufficient evidence to suggest
that the melatonin and placebo were significantly different, and it may be concluded,
based upon the study sample, design (e.g., inclusion and exclusion criteria) and
limitations, the effect of melatonin on the assessed self-reported outcome measures was
no different than taking placebo. However, due to the heterogeneity of the participants as
evidenced by the participant histories or by chance alone, there exists a possibility of a
Type II error that must be considered and not overlooked.
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APPENDIX
Capsule content was independently confirmed by the laboratory of Kevin J.
Tidgewell, Ph.D. (Assistant Professor of Medicinal Chemistry, Graduate School of
Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA) using high performance
liquid chromatography. The laboratory was blinded/masked as to intervention group of
capsules provided. Results of analysis is below:
Cap
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1
1
Avg. 1
25
25
25
Avg. 25
27
27
27
Avg. 27
41
41
41
Avg. 41
42
42
42
Avg. 42
60
60
60
Avg. 60

Area (210)
Height (210)
139.9546
71.647
139.5083
74.768
139.2811
75.171
139.5813333
73.862
89.4659
48.61
89.1073
50.113
90.3399
50.553
89.6377 49.75866667
0
0
0
0
0
0
0
0
99.1313
55.18
98.5686
56.892
98.7854
57.271
98.82843333 56.44766667
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Area (222)
144.1421
145.025
144.4363
144.5344667
96.1752
95.9579
96.9673
96.3668
0
0
0
0
109.4784
109.1269
109.4738
109.3597
0
0
0
0
0
0
0
0
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Height (222)
78.336
81.618
82.393
80.78233333
53.47
55.13
55.613
54.73766667
0
0
0
0
60.998
62.9
63.352
62.41666667
0
0
0
0
0
0
0
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Cap 1 [c]
Cap 25 [c]
Cap 41 [c]

Average
St. Dev.

222 nm

Area
Height
67.158 64.341
15
4
43.057 43.371
57
03
47.492 49.190
61
59

Area
Height
63.882 64.037
76
77
42.789 43.471
89
86
48.479 49.535
55
51

52.569
44
12.827
32

51.717
4
10.912
84

52.301
01
10.825
67

52.348
38
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56

52.234
06
9.6586
65

Average (all)
St. Dev. (all)
Average of Averages
(J7 - N7)
St. Dev. (J7-N7)

210 nm

52.234
06
0.3637
63

Results of capsule content in milligrams for melatonin group
41.6 comes from ug/mL melatonin/pill
41.6ug/ml
5mg mel

= average/ tab
X

7.800481 mg of melatonin: Capsule 1
5.192308 mg of melatonin: Capsule 25
5.853365 mg of melatonin: Capsule 41
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Average/ St.
pill
Dev./pill
64.85501 1.547191
86
5
43.17258 0.310177
967
82
48.67456 0.902322
459
42

